DE202017104675U1 - Composition with local anesthetic effect and its use - Google Patents

Abstract

Composition, in particular pharmaceutical composition, preferably for the prophylactic and / or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the urinary bladder, preferably of cystitis, wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts (a) chondroitin sulfate and / or a physiologically acceptable chondroitin sulfate salt (component (a)), (b) hyaluronic acid and / or a physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)); and (c) at least one local anesthetic (component (c)); contains.

Description

The present invention relates to the medical therapeutic field of treatment of preferably inflammatory diseases of the urogenital tract, in particular cystitis, such as interstitial cystitis.

In particular, the present invention relates to a composition, in particular a pharmaceutical composition, preferably having a local anesthetic effect, which is particularly suitable for the prophylactic or therapeutic treatment of inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the bladder, especially of cystitis, preferably interstitial cystitis. Likewise, the present invention also relates to corresponding uses of the composition according to the invention as well as a storage or application device containing the composition according to the invention. The present invention also relates to a packaging unit containing the storage or application device according to the invention and to a kit which contains the storage or application device according to the invention, the composition according to the invention and an instillation device which can be connected to the storage or application device.

The clinical picture of cystitis can generally be divided into two groups. In addition to such cystitis, which is caused by particular bacterial infections and which are usually treated with antibiotics or by surgical intervention to eliminate causes of infection, eg. As in obstructions or reflux, is to be treated, there are a number of inflammation of the bladder, which are not caused by infection. These include radiogenic cystitis (= radiation cystitis) and interstitial cystitis.

Radiogenic cystitis occurs in approximately 5% of patients treated for small bowel malignancies. This hemorrhagic cystitis usually occurs six months to ten years after irradiation and may be due to likely irreversible tissue changes.

The treatment options for radiogenic cystitis include antispasmodic therapy, e.g. As trospium chloride, darifenacin, etc. or a so-called hyperbaric oxygenation.

A much larger field is interstitial cystitis, especially as it affects a large group of people. Interstitial cystitis is sometimes defined as "chronic idiopathic cystitis of unclear genesis". Interstitial cystitis is difficult to diagnose and its treatment options are considered difficult. Interstitial cystitis is also subsumed under the term "painful bladder syndrome".

With regard to the aetiology, there are sometimes still no fully secured findings. In this regard, various hypotheses are discussed, such as release of inflammatory substances by mast cell activation due to different stimuli; occult infections; Increase the permeability of the bladder wall for toxic substances; immunological processes as well as hypersensitivity of nerve fibers with increase of nerve fiber density.

The diagnostic spectrum of interstitial cystitis includes, in addition to the micturition protocol and the pain diary with VAS (visual analogue scale) and the bacteriological examination to exclude a urinary tract infection and Urinzystologie to exclude a carcinoma in situ, a cystoscopy under anesthesia with possibly accompanying biopsy.

Interstitial cystitis is a chronic inflammatory disease of the bladder without detectable bacteria in the urine. Consequently, this is a non-bacterial cystitis. This is a condition that has not yet been completely clarified, and patients often suffer worse than from a tumor disease. The US National Health Institute has also classified interstitial cystitis as a higher-priority disease. The quality of life can be severely impaired by heavy urination, frequent urination during the day as well as in the night and increasing pain.

According to recent surveys, the incidence of the disease seems to be increasing. Patients in which the disease occurs are mostly middle-aged. The disease is more common in women than in men. One reason for this can be seen in the anatomy of the woman, whose urethra is shorter than that of the man. This leads to a higher susceptibility to ascending urinary tract infections. In women with recurrent (recurring) urinary tract infections, the mucous membrane of the bladder is more severely damaged. This constant irritation can be non-bacterial, especially chronic cause interstitial cystitis. Interstitial cystitis is thus predominantly diagnosed in women, although men may also be affected by the disease.

• - erhöhter Harndrang;
• - häufiges Wasserlassen;
• - Schmerzen des Beckens, des unteren Bauchraumes und des Darmes;
• - Beckendruck;
• - Schmerzen beim Wasserlassen, verbunden mit Abgabe geringster Mengen von Urin;
• - starker Schmerz während und nach dem Geschlechtsverkehr;
• - brennendes Schmerzgefühl insbesondere im Bereich der Harnblase;
• - massive Durchschlafprobleme durch Schmerzen;
• - Blut im Urin.

The most common symptoms of interstitial cystitis are (order of decreasing frequency):

• - increased urinary frequency;
• - frequent urination;
• - pelvic, lower abdominal and intestinal pains;
• - pelvic pressure;
• Pain in urination, associated with the delivery of minute amounts of urine;
• - severe pain during and after intercourse;
• - burning pain, especially in the bladder area;
• - massive sleep through pain;
• - Blood in the urine.

The main symptoms of interstitial cystitis are thus capacity loss of the bladder with filling-dependent pain and frequent and massive urinary urgency. One speaks also of the Triad: "frequency, urgency, pain" (frequency, urgency, pain).

The aforementioned symptoms of interstitial cystitis may be e.g. For example, increased sensitivity to pain or psychological factors may increase it. In addition, a disruption of the composition of the glycosaminoglycan layer was shown, and immunohistochemical investigations show u. a. a reduced chondroitin sulphate staining.

Without wishing to be limited or limited to one theory, the development and development of interstitial cystitis can be explained as follows: gaps in the protective layer of the bladder mucosa, the so-called glycosaminoglycan layer, cause bacteria, microcrystals, proteins and / or harmful dissolved urinary components such as urea, directly into deeper layers of the bladder mucosa and cause there further damage or irritation.

The damage to the bladder mucosa and the resulting chronic inflammation leads to repair processes that are often accompanied by scarring. This can lead to limited elasticity of the urinary bladder wall and to an increasing loss of capacity of the bladder. In the late stage of interstitial cystitis, a shrinking blister may develop and surgical removal of the bladder may be necessary in some circumstances. Therefore, early detection and therapy to prevent the late stage of interstitial cystitis is of great importance.

The main cause of interstitial cystitis is the damage to the bladder mucosa. The bladder mucosa is shielded by a protective layer containing, inter alia, hyaluronic acid against microorganisms, carcinogenic substances, and other harmful substances found in the urine. This protective layer, which is also called Glykosaminoglykanschicht (GAG layer) and which contains hyaluronic acid as well as chondroitin sulfate, heparin and Pentosanpolyphosphat as important ingredients is extremely water-binding and forms a kind of "water film" and thus a further physical barrier against harmful substances in the Urine.

In patients with cystitis, and especially with interstitial cystitis, there are defects in this protective layer of the bladder mucosa. In particular, a loss of hyaluronic acid has been noted.

Other causes of interstitial cystitis may include As autoimmune reactions that target the body's own cells in the bladder, or be former chronic bacterial infections.

The typical symptoms of interstitial cystitis are frequent urination, increased urinary frequency and in some cases uncontrolled urination (urinary incontinence) and blood in the urine. Severe pain develops especially when the bladder is full. Other hallmarks include pelvic pain, lower abdominal cavity and perineal pain, pelvic pressure and painful urination associated with urine being dispensed drop by drop. Also during and after intercourse You often experience severe pain. In many cases, the complaints of the patients cause such enormous suffering that also surgical procedures up to the cystectomy are required.

For the diagnosis of interstitial cystitis it is important that other bladder diseases with similar symptoms are ruled out. In a first step, it must be clarified whether the patient is suffering from a previous operation (for example in the lower abdomen), whether the bladder infection was caused by radiotherapy or chemotherapy, or if recurrent, recurrent infections were present or present. Subsequently, it should be investigated whether gynecological, neurological, psychiatric and / or rheumatic diseases can be ruled out. Furthermore, complaints of spinal acid and allergies should be excluded.

As part of the investigation or diagnosis of interstitial cystitis, for example, in a laboratory, a urine culture and an examination of the cellular components in urine (urinary cytology) are performed. For female patients, a vaginal swab should be used to exclude sexually transmitted diseases.

Sensitivity to pain is assessed by palpation of the vagina. In male patients, bacterial culture from the ejaculate is applied to exclude bacterial inflammation of the prostate. To exclude prostate cancer, the value of the prostate-specific tumor marker (PSA = prostate-specific antigen) is determined. By means of an ultrasound examination the residual urine is determined and an ingrowth of the prostate into the bladder is excluded.

Further examination may also be performed by cystoscopy. The cystoscopy can be performed under anesthesia. Typical signs of interstitial cystitis, which can be manifested by cystoscopy, are increased ingrowth of blood vessels into the bladder mucosa, accumulation of fluid in the mucous membrane, rupture of the mucosa (glomeruli), punctate hemorrhage after expansion of the bladder under pressure by water infusion (hydrodistension) and In about 10 to 20% of patients signs of bladder ulcers (Hunner's Ulcera).

In interstitial cystitis, patients feel a strong urge to urinate even with small quantities of urine; its bladder capacity is reduced. For the diagnosis of interstitial cystitis, therefore, the determination of the maximum filling volume and then a comparative bladder capacity measurement (cystometry) can be performed.

Studies on interstitial cystitis show that bladder epithelium or urothelium of the bladder is deficient in the presence of cystitis. This weakening contributes significantly to the clinical symptoms of interstitial cystitis.

As far as the treatment of interstitial cystitis is concerned, to date there is neither a fully effective remedy nor a thorough treatment that is effective for all patients.

Thus, a composition based on pentosanpolysulfate sodium is known in the prior art. It is believed that the effect is to repair a thin or damaged bladder wall. The treatment successes are not always satisfactory.

Basically, antidepressants, such as tricyclic antidepressants, have been shown to be effective in alleviating pain and micturition frequency in interstitial cystitis, although not always a desirable treatment success is guaranteed.

Other oral drugs include anti-inflammatory agents, anti-spasmodics, antihistamines and muscle relaxants. However, such drugs can relieve the disease only to a certain extent. A sustainable therapeutic success is usually not possible with these drugs.

Furthermore, bladder instillations can be performed with certain substances. Thus, a bladder distension can be realized, wherein the bladder is filled with water under general anesthesia for stretching. Although this is primarily a diagnostic procedure for interstitial cystitis, such a procedure can also be used therapeutically.

In addition, DMSO (dimethylsulfoxide) can be filled as a drug directly into the bladder, in which case an anti-inflammatory effect should occur. DMSO can be mixed with steroids, heparin and other ingredients to form a "bladder cocktail". However, the side effects are often high.

Other bladder instillations, such as using oxychlorose sodium, are for the most part very painful and require general anesthesia. Silver nitrate is rarely used and is considered outdated therapy.

Other treatments, such as targeted nutrition while avoiding certain foods, especially acidic, spicy foods, can only marginally reduce the severity of the symptoms. Interstitial cystitis can also be exacerbated by smoking, coffee or tea and alcoholic beverages.

Self-help techniques can slightly improve quality of life and reduce the incidence and severity of seizures. These include, for example, a change in lifestyle, stress reduction, visualization, biofeedback, bladder training and exercise. A lasting therapeutic success is often not possible with these methods.

Bladder surgery may be considered for a small number of patients with severe symptoms who do not respond to other treatments. In some cases, however, the symptoms do not get better. Several types of surgery have been used to treat interstitial cystitis, including cystectomy and urinary diversion. However, due to the severity of the surgical procedure, surgery should always be the last resort.

The treatment options are therefore just as diverse as overall unsatisfactory. In summary and in addition to the above, the following treatment methods for interstitial cystitis have been considered so far. Innervation-affecting drugs (antispasmodics, antihistamines); a cytodestive therapy followed by regeneration (eg DMSO, hydrodistension); a cytoprotective therapy to restore the glycosaminoglycan layer (heparin, pentosulfan polysulfate). In the context of conservative therapy, it is about the reduction of symptoms by means of orally administered substances, such as antispasmodics (low success); antihistamines; Antidepressants, especially tricyclics (amitriptyline); Cytoprotective agents, such as pentosulfan polysulfate (very long latency up to two years, until success becomes measurable); Immunosuppresives such as azathioprine, cyclosporin, chloroquine; Calcium antagonists, z. B. nifedipine. The hydrodistension is the overstretching of the bladder by means of an intravesically inserted balloon. As a rule, it is stretched over a period of three hours, but the therapeutic effect is equally low and only short-lasting. There are also various intravesical pharmacotherapeutic measures, in particular for restoring the glycosaminoglycan layer. For this purpose, as previously discussed, pentosan polysulfate, heparin or DMSO used. Alternative treatment methods are also carried out. These include relaxation exercises, behavioral training, acupuncture, neuromodulation and dietary measures.

In the prior art, other compositions or methods are proposed for the treatment of cystitis, such as interstitial cystitis; However, these do not always have the desired or required efficiency. In addition, such prior art compositions are sometimes not sufficiently storage stable.

In particular, on the basis of the known therapeutic approaches also a sustained and in particular after administration or application underlying compositions timely incipient pain relief or treatment is not given, so that in the result in the prior art, there is no satisfactory pain therapeutic approach.

The WO 2004/073584 A2 relates to a pharmaceutical composition for use in the bladder of a patient, the composition comprising chondroitin sulfate. This document focuses on the use of a single drug.

Furthermore, the concerns US Pat. No. 6,083,933 Chondroitin sulfate-containing compositions which can be used in the treatment of interstitial cystitis. However, the use of a mono-composition which contains no other active ingredients other than chondroitin sulfate does not always suffice for the effect of the cystitis to be treated.

In addition to the provision of high efficacy with respect to the underlying disease, in view of the medical-therapeutic requirements for suitable instillation compositions and their handling, there is a great need in the art for stable compositions or compositions having a high durability, ie Instillation, which over a correspondingly long period of time have defined or constant (product) properties, for example with regard to the stability of the active substances with associated therewith small amounts of sometimes toxic degradation products, pH stability, constant viscosity or the like. In particular, there is a corresponding need for compositions with high storage stability, ie those compositions for instillation, which are stable or constant over a long period in terms of their active ingredients or their physicochemical properties.

Because known from the prior art compositions which are administered in the context of the treatment of particular inflammatory diseases of the genitourinary tract, such as cystitis, sometimes have not optimal stability behavior, which also is not always optimal effectiveness. In this context, there is in particular a danger that, within the scope of the underlying treatment, prematurely degraded compositions with possibly reduced amount of active ingredient or correspondingly increased proportion of possibly harmful degradation products may be used, which, however, may be detrimental to a thorough treatment success.

Against this background, it is therefore an object of the present invention to provide a corresponding composition, in particular a pharmaceutical composition, preferably for the prophylactic or therapeutic treatment of preferably inflammatory treatments of the genitourinary tract, for example cystitis, in particular interstitial cystitis, which have the disadvantages of the prior art described above at least largely avoids the technique or at least mitigates it.

In particular, such a composition should have an improved stability compared to conventional, for the treatment of particular inflammatory diseases of the genitourinary tract, especially cystitis, such as interstitial cystitis, certain pharmaceutical compositions or preparations, in particular storage stability, especially with regard to longer periods constant Drug levels and physicochemical properties of the underlying compositions.

Yet another object of the present invention is also to provide a corresponding composition which also has a high efficiency in the treatment of preferably inflammatory diseases of the genitourinary tract, in particular cystitis, preferably interstitial cystitis, while equally improving their handling and tolerability should be.

In particular, it is also intended to provide such a composition which has improved analgesic or pain-relieving or locally anesthetic properties, in particular, a rapid entry with long duration of action of the pain-relieving effect being provided.

To achieve the object described above, the present invention proposes - according to a first aspect of the present invention - a composition, in particular a pharmaceutical composition, (for use) according to claim 1; Further, particularly advantageous embodiments of the composition according to the invention are the subject of the relevant additional claim and the related subclaims.

Furthermore, the present invention - according to a second aspect of the present invention - also relates to the use of the composition according to the invention according to the related independent use claims; Further, particularly advantageous embodiments of the use according to the invention are the subject of the relevant subclaims.

In addition, according to a third aspect of the present invention, the present invention relates to a storage or application device comprising the composition according to the invention, as defined in the independent claims relating thereto relating to the storage or application device; Further, particularly advantageous embodiments of the storage or application device according to the invention are the subject of the relevant subclaims.

Moreover, according to a fourth aspect of the present invention, the present invention also relates to a packaging unit containing the storage device according to the invention in accordance with the independent claim relating to the packaging unit thereof; Further, particularly advantageous embodiments of the packaging unit according to the invention are the subject of the relevant subclaim.

Finally, according to a fifth aspect of the present invention, the present invention also relates to a kit, in particular an installation system, as defined in the independent claim relating to the kit; Further, particularly advantageous embodiments of the kit according to the invention are the subject of the relevant subclaim.

It goes without saying in connection with the following statements that embodiments, embodiments, advantages and the like, which are listed below for purposes of avoiding repetition only as an aspect of the invention, of course also apply correspondingly with respect to the other aspects of the invention, without this being so requires a separate mention.

In the context of the present invention, in the context of the present invention, all the relative weight percentages given below, in particular quantities, are to be selected by the person skilled in the art in such a way that they include all the components or ingredients, in particular as defined below always add or add up to 100% or 100% by weight; but this is self-evident to the person skilled in the art.

Furthermore, the person skilled in the art may deviate from the concentrations, weights, quantities and ranges indicated below, depending on the application or the individual case, without departing from the scope of the present invention.

In addition, all of the values or parameters specified below or the like can in principle be determined or determined using standardized or explicitly stated determination methods or otherwise using methods of determination or measurement known per se to those skilled in the art.

The term "drug" (synonymously also "pharmaceutical"), as used in the context of the present invention, is to be understood very broadly and includes not only pharmaceuticals or pharmaceuticals as such (ie in terms of pharmaceutical law), but above all Also so-called medical devices and beyond but also homeopathic and nutritional supplements, as well as cosmetics and utensils. In other words, therefore, the composition of the invention may be in the form of a drug (pharmaceutical), medical device, homeopathic, dietary supplement, cosmetic or in the form of a commodity.

In the context of the present invention, the term "local anesthetic" as used in the present invention generally means local anesthetics or for local analgesia or anesthesia, in particular wherein the local anesthetics which can be used according to the invention should have no euphoric or addictive effect. The chemical structure of the local anesthetics which can be used according to the invention can basically be similar; it generally comprises a lipophilic aromatic ring structure, an intermediate chain and a hydrophilic amino group. After the intermediate chain, a distinction is made between aminoesters ("ester type") and aminoamides ("amide type"). In particular, without wishing to be bound or limited to this theory, local anesthetics exert their pharmacological action on the cell membrane of nerve cells, especially where the formation and transmission of sensations such as temperature, pressure or pain are locally attenuated or completely disrupted.

Having said that, the present invention will now be explained in detail below.

1. (a) Chondroitinsulfat und/oder ein physiologisch verträgliches Chondroitinsulfat-Salz (Komponente (a));
2. (b) Hyaluronsäure und/oder ein physiologisch verträgliches Hyaluronsäure-Salz (Hyaluronat) (Komponente (b)); und
3. (c) mindestens ein Lokalanästhetikum (Komponente (c));

enthält.The present invention - according to a first aspect of the present invention - is thus a composition, in particular pharmaceutical composition, preferably with local anesthetic effect, preferably for the prophylactic or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, especially of inflammatory diseases of the bladder, preferably from Cystitis, especially of interstitial cystitis,
wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts

1. (a) chondroitin sulfate and / or a physiologically acceptable chondroitin sulfate salt (component (a));
2. (b) hyaluronic acid and / or a physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)); and
3. (c) at least one local anesthetic (component (c));

contains.

For the Applicant has found in the context of the present invention in a surprising manner that the targeted combination of chondroitin sulfate or a physiologically acceptable chondroitin sulfate salt and hyaluronic acid or a physiologically acceptable hyaluronic acid salt (hyaluronate) on the one hand with a local anesthetic in which it in particular and as may be mentioned below may be lidocaine or lidocaine hydrochloride, leads to compositions which are superior to the compositions of the prior art in the treatment of inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the bladder, such as cystitis or preferably interstitial cystitis have significantly improved properties, particularly with regard to high efficacy or efficacy in the treatment of the underlying disease, while ensuring sustainable (ie, in particular, a fast-onset and long-lasting) (local) anesthetic effect and thus an improved pain-therapeutic effect. In addition, the compositions according to the invention, while having very good compatibility, also have improved stability, in particular storage stability.

In the context of the present invention, therefore, a highly effective drug or medicament or (medicine) product is provided with the composition according to the invention, which due to the specific combination and coordination of the components used according to the invention, in particular based on a ternary combination using the components (a ), (b) and (c), a high efficacy with respect to the underlying disease, in particular cystitis or preferably interstitial cystitis, has, at the same time excellent analgesic properties or analgesic properties are present. Due to the excellent (local) anesthetic properties, the high suffering of the patients affected by the disease is significantly reduced, which is associated with a corresponding increase in quality of life.

With regard to the underlying disease of the genitourinary tract or bladder, the measures according to the invention on the basis of the listed active ingredient combination intermesh, as it were, and reinforce each other beyond the effect of the individual measures, which leads to the corresponding properties of the compositions according to the invention having the high stability and effectiveness ,

The composition or combination according to the invention leads, via a surprisingly found stability, in particular storage stability, as further mentioned below, also overall to a particularly good activity with regard to the underlying diseases of the bladder, both the reduction of the bladder wall damage and the analgesic or (local) anesthetic properties.

One possible explanation for the outstanding effect of the composition according to the invention can be seen in the fact that the active substances of the composition according to the invention interact in a particularly effective manner, in particular with the urothelium of the urinary bladder, without being limited to this theory. or incorporation of the active substances is present on or in this layer, resulting in a repair of the damaged by the disease glycosaminoglucan layer or to a related regeneration, in which in particular the active components (a) and (b) fill up corresponding damage or compensate. The reduction in the permeability of the urothelium associated with this mode of action-which in a sense equates to a "sealing effect" on the urine or urine present in the urinary bladder-leads to a marked alleviation of the disease-related symptoms, with additional or accompanying pain relief on the basis of a In addition, due to the local anesthetic present in the composition in accordance with component (c), or such an effect is correspondingly enhanced. By the purposeful use of a local anesthetic in the form of component (c), in this context, a rapidly onset of pain, ie, an analgesic effect occurring immediately or promptly after application or instillation of the composition according to the invention, is simultaneously caused. By the above-mentioned repair mechanisms based on the active components (a) and (b) are also the disease-related symptoms are mitigated so that the underlying symptoms of pain are alleviated or alleviated, in particular with regard to a long-term effect.

In this context, the mode of action of the composition according to the invention with regard to the active components (a) and (b) - without wishing to be bound or limited to this theory - can be seen in particular in a significant physical interaction in which the active ingredients according to component (a) or (b) are incorporated or incorporated into the urothelium or attach to it, so that caused by particular inflammatory reactions loss of chondroitin sulfate or hyaluronic acid in the bladder wall or in the urothelium is compensated or compensated. Thus, there is a certain degree of regulation of the permeability or permeability of the bladder wall, which leads to a containment of the inflammatory reaction and thus to a support of the wound healing and thus to an overall improvement in the state of health. The composition according to the invention forms quasi-in particular on the basis of components (a) and (b) a physical protection of the bladder epithelium from irritating substances, such as bacteria, microcrystals or the like, the composition according to the invention as replacement and protection of the glycosaminoglycan layer in the bladder and the draining urinary tract. By the underlying repair mechanism with the containment of inflammatory reactions is equally a pain-reducing effect. The targeted use of a local anesthetic according to component (c), which is used in particular in the form of lidocaine or lidocaine hydrochloride, thereby leading to even further improved properties in terms of effective pain reduction, especially with regard to a rapid onset of action when using the composition according to the invention.

The Applicant has found in the context of the present invention, completely surprising that the specific combination of the aforementioned active components (a) and (b) on the one hand with the local anesthetic component (c) on the other hand to a particularly good efficacy of the composition according to the invention both in terms of analgesic properties as well as the underlying repair of urinary bladder urothelium: The underlying synergism can be explained - without wishing to be bound or limited to this theory - by improving the analgesic effect of the local anesthetic in so far as it improves its performance, in particular as a result of the components (a) or (b) reduced tissue irritation or lesions in the bladder mucosa also an improved interaction of the local anesthetic (c) is made possible at the site of action, wherein in the area of the urothelium a certain accumulation of local anesthetics Hetikums is made possible, so that with regard to the component (c) a certain depot effect at the site of action results, whereby the effect of the local anesthetic is in turn reinforced or extended. In addition, due to the rapid onset of pain relief, as evoked in particular by component (c), an extended residence time of the composition according to the invention in the urinary bladder can be realized, especially as the pain relief also reduces the urgency or the instilled composition is perceived as less unpleasant , Consequently, there is also an increased duration of action of the active components (a) and (b), so that the effect of the components (a) and (b) is also enhanced, in particular with regard to the repair of the urothelium. The components (a) and (b) based on chondroitin sulfate or hyaluronic acid on the one hand and the local anesthetic according to component (c) thus mutually reinforce each other in their action.

As a result, the use of the composition according to the invention thus leads to a timely and also long-lasting pain relief and after only a few treatments in the patients affected by the underlying disease to a significantly improved health status, along with a significant increase in quality of life and reducing the suffering. In this regard, the composition according to the invention can thus, so to speak, at least also serve for the temporary replacement of a defective glycosaminoglycan layer of the urinary bladder or of the urothelium.

Furthermore, as far as the composition according to the invention is concerned, it may also comprise (d) a buffer system, in particular selected from the group of dihydrogenphosphate / monohydrogenphosphate buffer system, citric acid / citrate buffer system, carbonic acid / bicarbonate buffer system, carbonic acid / silicate buffer system and acetic acid / acetate Buffer system, preferably selected from the group of dihydrogen phosphate / monohydrogen phosphate buffer system and citric acid / citrate buffer system, preferably dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)). Thus, according to the invention, it can thus be provided in particular that the composition additionally contains (d) a buffer system, preferably a dihydrogenphosphate / monohydrogenphosphate buffer system, (component (d)). As a result, the properties of the composition according to the invention can be further improved.

Similarly, it may be provided according to the invention that the composition also contains (e) at least one physiologically acceptable electrolyte (component (e)).

Surprisingly, in the context of the present invention, it was also found that based on the conception according to the invention a special composition - namely as component (a) chondroitin sulfate or a physiologically acceptable chondroitin sulfate salt, as component (b) hyaluronic acid or a physiologically acceptable hyaluronic acid salt , as component (c) at least one local anesthetic, as component (d) the buffer system in question and optionally as component (e) contains a physiologically acceptable electrolyte - for purposeful application, in particular instillation, in the treatment of the diseases of urogenital tract in question , In particular, cystitis or interstitial cystitis, can be provided, which in addition to the prior art with high efficacy and very good compatibility also has an improved stability, in particular storage stability.

1. (a) Chondroitinsulfat und/oder ein physiologisch verträgliches Chondroitinsulfat-Salz (Komponente (a));
2. (b) Hyaluronsäure und/oder ein physiologisch verträgliches Hyaluronsäure-Salz (Hyaluronat) (Komponente (b));
3. (c) mindestens ein Lokalanästhetikum (Komponente (c));
4. (d) ein Puffersystem, insbesondere Dihydrogenphosphat/Monohydrogenphosphat-Puffersystem, (Komponente (d)); und
5. (e) mindestens einen physiologisch verträglichen Elektrolyten (Komponente (e));

enthält,
wobei die Zusammensetzung einen pH-Wert in einem Bereich von 5,5 bis 8,0 aufweist und/oder wobei die Zusammensetzung auf einen pH-Wert in einem Bereich von 5,5 bis 8,0 eingestellt ist.According to the present aspect, the present invention thus also relates to a composition, in particular a pharmaceutical composition, preferably having a local anesthetic effect, preferably for the prophylactic or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the bladder, preferably of cystitis, more preferably of interstitial cystitis, preferably a previously defined composition,
wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts

1. (a) chondroitin sulfate and / or a physiologically acceptable chondroitin sulfate salt (component (a));
2. (b) hyaluronic acid and / or a physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b));
3. (c) at least one local anesthetic (component (c));
4. (d) a buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)); and
5. (e) at least one physiologically acceptable electrolyte (component (e));

contains
wherein the composition has a pH in a range of 5.5 to 8.0 and / or wherein the composition is adjusted to a pH in a range of 5.5 to 8.0.

In this context, the targeted adjustment of the pH of the composition according to the invention in the abovementioned ranges leads to a further stabilization of the composition according to the invention. Moreover, the inventively provided ranges of the pH of the composition according to the invention also lead to the local anesthetic used according to the invention in particular in the form of lidocaine hydrochloride being present in a predominantly protonated form, which enhances the stability of the underlying composition and therefore also the availability of component (c). beneficial at the site of action.

On the basis of the composition according to the invention thus a highly effective drug or drug or (medical) product is provided, which due to the specific combination and coordination of the underlying components excellent stability, in particular storage stability, having no substantial and even after correspondingly long storage periods both the effectiveness and the compatibility negatively affecting degradation of the active ingredients or ingredients of the composition itself is present.

What in the context of the present invention in addition to the high efficacy associated with the present invention provided local anesthetic effect, in view of the prophylactic or therapeutic treatment of inflammatory diseases of the urogenital tract, in particular of inflammatory diseases of the bladder, preferably of cystitis or interstitial cystitis, also As regards the improvement of the stability, in particular storage stability, of the composition according to the invention, which is found in a completely surprising manner, the concentrations of the components present in the composition according to the invention, in particular with regard to the components (a), (b) and / or (c) a corresponding meaning too. For the Applicant has found in this context that based on the inventively preferred concentrations, as follows defined, and the associated quantities of substances, in particular on the basis of components (a) and (b), there is a corresponding stability and optimum action.

The measures according to the invention also interlock, as it were, with regard to the use of a buffer system according to component (d) and the setting of a specific pH and reinforce each other with regard to ensuring high stability, in particular storage stability, and high efficiency over the Effect of the individual measures, so that in this regard, there is a synergistic effect, as shown by the following examples. Without wishing to be limited or limited to the following theory, with regard to the composition according to the invention as a result an optimal formation of a matrix or a hydrogel based on the underlying components, in particular based on the components (a) and (b ), which counteracts the degradation of the underlying active ingredients or a storage or time-related change in the physicochemical properties, such as viscosity or the like, and is also beneficial to the effectiveness. Consequently, there is a corresponding increase in stability, along with longer storage periods.

In the context of the present invention, the optionally present buffer system according to component (d) is used in particular for stabilizing the composition according to the invention. In particular, the setting of a constant pH by means of the buffer system surprisingly leads to an undesirable degradation of the active ingredients, in particular of components (a) and (b), being effectively counteracted during storage even over a relatively long period of time. In this way, the stability or storability of the composition according to the invention is improved.

With regard to the stability behavior, it has also been found in the context of the present invention in a completely surprising manner that the preferred use of a special phosphate buffer (system) according to component (d), namely in particular in the form of a dihydrogen phosphate / monohydrogen phosphate buffer system, to a further improvement Product properties leads. Due to the use of the special phosphate buffer (system), there is also a further improvement in the underlying stability properties. Likewise, without wishing to be limited to this particular theory, the use of a specific buffer also results in further stabilization of the matrix or hydrogel resulting from components (a) and (b), and also as a result of that on the basis of the special buffer system an optimal stabilization of the pH is present, which benefits the stability of the composition as a whole.

In addition, by the use of the buffer system according to component (d) and adjusting the inventively provided ranges of the pH of the composition also with respect to the component (c) stabilization possible, and in particular in so far as used in a preferred manner Lidocainhydrochlorid is present in protonated form, which is both the stability and the availability of the underlying component (c) at the site of action beneficial.

In addition, the composition according to the invention is also characterized by a good compatibility with at the same time excellent efficacy or effective efficiency with regard to the treatment of the underlying diseases, in particular cytitis or interstitial cystitis.

Due to the defined and also after long storage periods present constant physico-chemical properties of the composition according to the invention, the handling or application, in particular with regard to the instillation into the bladder, improved, which also leads to an increased acceptance by the patient and to a reduction of misuse leads.

On the basis of the conception according to the invention, a total of temporal degradation or time-related degradation of the corresponding active ingredients or ingredients is thus counteracted, so that even after correspondingly long periods, high or constant active substance concentrations are present at at least substantially constant pH. This also ensures that sometimes toxic or harmful degradation products are not present or only in small amounts, which is equally positive for the efficiency and compatibility of the composition according to the invention.

Overall, based on the conception according to the invention, a composition is thus provided which is outstandingly suitable for the treatment of preferably inflammatory diseases of the urogenital tract, in particular of inflammatory diseases of the urinary bladder, preferably of cystitis or interstitial cystitis, and has significantly improved properties over the prior art.

As regards the component (a) used according to the invention in the form of chondroitin sulfate or of the physiologically compatible chondroitin sulfate salt (also referred to as chondroitin polysulfate or chondroitin polysulfate salt), it has proved to be advantageous according to the invention if the composition contains chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) in a concentration in a range of (2 ± 0.5) mg / ml to (25 ± 2) mg / ml, especially in a range of (3 ± 0.5 ) mg / ml to (22 ± 2) mg / ml, preferably in the range of (4 ± 0.5) mg / ml to (20 ± 2) mg / ml.

In particular, it may be provided according to a first embodiment of the present invention that the composition of the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) in a concentration of (20 ± 1.5) mg / ml, in particular a concentration of (20 ± 1) mg / ml, preferably in a concentration of (20 ± 0.5) mg / ml, more preferably in a concentration of about 20 mg / ml.

In addition, according to an alternative embodiment, the composition may contain the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) in a concentration of (4.5 ± 0.4) mg / ml, in particular in a concentration of (4 , 5 ± 0.3) mg / ml, preferably at a concentration of (4.5 ± 0.15) mg / ml, more preferably at a concentration of about 4.5 mg / ml.

In particular, the Applicant has found that, as stated above, with respect to the above-mentioned concentration ranges - in particular in cooperation with component (b) - a corresponding stability and effectiveness maximum with regard to the composition according to the invention is present.

In addition, the molecular weight (synonymously also called "molecular weight") of component (a) is of great importance:

Thus, it can be provided according to the invention that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) has a number average molecular weight (molecular weight) M _n in the range from 2 kDa to 200 kDa, in particular in the range from 5 kDa to 150 kDa , preferably in the range of 10 kDa to 100 kDa, preferably in the range of 12 kDa to 75 kDa.

In particular, the chondroitin sulfate or the physiologically tolerable chondroitin sulfate salt (component (a)) may have a weight-average molecular weight M _w in the range from 10 kDa to 200 kDa, in particular in the range from 15 kDa to 175 kDa, preferably in the range from 20 kDa to 150 kDa, preferably in the range of 30 kDa to 120 kDa have.

In addition, the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) may have a centrifuge-average molecular weight M _z in the range from 30 kDa to 1000 kDa, in particular in the range from 40 kDa to 800 kDa, preferably in the range from 50 up to 600 kDa, preferably in the range from 100 kDa to 450 kDa.

In this context, the polydispersity index (PDI) also has a corresponding importance: In this regard, it may be provided according to the invention that the chondroitin sulfate or the physiologically compatible chondroitin sulfate salt (component (a)) has a polydispersity index (PDI), calculated as the quotient of weight-average Molecular weight M _w and number average molecular weight M _n (M _w : M _n ), of at least 1, in particular at least 1.2, preferably at least 1.5, preferably at least 2, having.

In addition, the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) can have a polydispersity index (PDI), calculated as the quotient of weight-average Molecular weight M _w and number average molecular weight M _n , of at most 30, in particular at most 20, preferably at most 10, preferably at most 8, have.

Furthermore, the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) can have a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , in the range from 1 to 30, in particular in the range from 1 , 2 to 20, preferably in the range of 1.5 to 10, preferably in the range of 2 to 8, have.

The abovementioned properties of component (a) with regard to the molecular weight or the molar mass or the relevant polydispersity index lead - without wishing to be limited or limited to this theory - to a further improved design of the matrix on which the composition according to the invention is based, in particular also with regard to the formation of a hydrogel, with appropriate stabilization of the respective active ingredients or ingredients. Equally, the molecular weights or molecular masses in question with respect to component (a) also lead to a good efficiency of the composition according to the invention with regard to the underlying disease, in particular - albeit without wishing to be limited or limited by this theory - as a result of a good or no Optimal interaction with or attachment to the urothelium of the bladder. Without wishing to be limited to a theory in this regard, this particular chondroitin sulfate is due to its molecular structure in a special way to - in particular in conjunction with the component (b) - to regenerate the glycosaminoglycan layer of the urothelium or to a certain extent to refill, thereby the permeability of this layer is lowered. As a result, the protective function of the glycosaminoclycan layer or the mucous layer of the urothelium (mucin layer) is increased, so that it can therefore also come to a significant relief or even healing of the disease symptoms.

As regards the determination of the molecular weight of the component (a) used according to the invention, the number average molecular weight M _n or the weight average molecular weight M _w or the centrifuge average molecular weight M _z and / or the polydispersity index (PDI) of the chondroitin sulfate or of the physiologically tolerable Chondroitin sulfate salt (component (a)) in particular by gel permeation chromatography (GPC) or according to DIN 55672-3: 2016-03 determined.

In particular, the number average molecular weight M _n or the weight average molecular weight M _w or the centrifuge average molecular weight M _z or the polydispersity index (PDI) of the chondroitin sulfate or of the physiologically acceptable chondroitin sulfate salt (component (a)) can be determined by gel permeation chromatography (GPC), in particular at a temperature in the range from 20 ° C to 40 ° C or with 0.1 mol / l NaCl solution in deionized water as eluant and / or at a solution of chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt with a Concentration of 3 g / l and / or using a dextran / pullulan standard as a calibration reagent and / or according to DIN 55672-3: 2016-03 be determined.

In a preferred manner according to the invention, the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) may be of marine origin. In this regard, the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) can be obtained from cartilaginous fish, in particular sharks, preferably shark cartilage. The Applicant has surprisingly found in this regard that such a chondroitin sulfate of marine origin, especially in the treatment of inflammatory diseases of the urogenital tract, such as cystitis, especially interstitial cystitis, leads to particularly good results, especially if this in purposeful combination with the hyaluronic acid according to component ( b) is used. The relevant isolation of the active substances is familiar to those skilled in the art, so that in this regard no further explanations are required.

According to the invention, it is provided in particular that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) is in the form of an alkali metal salt, preferably in the form of a sodium salt, which leads to particularly good results in the context of the present invention.

According to the invention, the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) may preferably be present in the form of chondroitin sulfate sodium.

According to the invention, the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) may additionally be selected from the group of chondroitin 4-sulfate, chondroitin 6-sulfate, chondroitin 2,6-sulfate, chondroitin-4,6 sulfate and their combinations or mixtures, preferably chondroitin-2,6-sulfate (chondroitin sulfate D). The abovementioned special chondroitin sulfates are also employed in a preferred manner in the form of their alkali metal salts, preferably sodium salts, which is associated with particularly good results with regard to the treatment of preferably inflammatory diseases of the genitourinary tract, such as cystitis, in particular interstitial cystitis.

In the context of the present invention, component (a) of the composition according to the invention may preferably be based on a sterile and / or highly purified solution or suspension, in particular of the sodium salt of chondroitin sulfate.

Chondroitin sulfate or chondroitin sulfate salt which can be used in the context of the present invention is generally available commercially, for example from Nexira, Rouen (FR), Artesan Pharma GmbH & Co. KG or from Pharma Greven GmbH, Greven (DE).

For further details on the term chondroitin sulfates, see RÖMPP Chemielexikon, 10th edition, Volume 1, 1996, Georg Thieme Verlag Stuttgart / New York, page 736, keyword: "chondroitin sulfates" , as well as the literature referenced there are referenced, the entire disclosure content of the aforementioned literature is hereby incorporated by reference in its entirety.

As regards the further component in the form of the hyaluronic acid or the physiologically acceptable hyaluronic acid salt according to component (b), which is used for the composition according to the invention, in particular the following should be mentioned:

In this connection, according to the invention, it can generally be provided that the composition comprises the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) in a concentration in a range of (1 ± 0.5) mg / ml to (20 ± 2) mg / ml, especially in the range of (2 ± 0.5) mg / ml to (18 ± 2) mg / ml, preferably in the range of (3 ± 0.5) mg / ml to (16 ± 2) mg / ml.

According to the invention, it may also be provided in particular that the composition comprises the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) in a concentration of (16 ± 1.2) mg / ml, in particular in a concentration of (16 ± 0.8) mg / ml, preferably at a concentration of (16 ± 0.4) mg / ml, more preferably at a concentration of about 16 mg / ml. In the abovementioned concentration ranges, particularly good properties with regard to stability and effectiveness are obtained, in particular based on interaction in particular with components (a) and / or (c) and / or optionally (d) or the specific pH of the composition according to the invention.

In particular, with regard to the stability, preferably storage stability, the composition of the invention and their effectiveness in the treatment of inflammatory diseases of the genitourinary tract, especially cystitis, preferably interstitial cystitis, particularly good results are achieved when the hyaluronic acid a specific molecular weight or a special Has molecular weight, as stated below.

In this context, it is preferred according to the invention if the hyaluronic acid or the physiologically tolerable hyaluronic acid salt (component (b)) has a number-average molecular weight (molecular weight) M _n in the range from 10 kDa to 300 kDa, in particular in the range from 20 kDa to 275 kDa, preferably in the range from 30 kDa to 260 kDa, preferably in the range from 50 kDa to 250 kDa, particularly preferably in the range from 50 kDa to 200 kDa.

In particular, the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) may have a weight-average molecular weight M _w in the range from 10 kDa to 500 kDa, in particular in the range from 20 kDa to 450 kDa, preferably in the range from 50 kDa to 425 kDa, preferably in the range of 100 kDa to 400 kDa, particularly preferably in the range of 150 kDa to 395 kDa.

In addition, the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) may have a centrifuge-median molecular weight M _z in the range from 80 kDa to 1,500 kDa, in particular in the range from 100 kDa to 1,250 kDa, preferably in the range from 200 kDa to 1,000 kDa, preferably in the range of 300 kDa to 750 kDa.

On the basis of the abovementioned molecular weights, a particularly good stabilization and effective efficiency of the composition according to the invention results, in particular in purposeful tuning and combination with the corresponding molecular weights of component (a), in particular because - without wishing to be limited to this theory - on the basis of the abovementioned Molecular weights optimal matrix or hydrogel education with appropriate stabilization and further optimized interaction is ensured in particular with the urothelium of the bladder. This is alike the effectiveness of the composition according to the invention is beneficial, even with regard to the local anesthetic component (c), the Einwirkverhalten is equally improved further.

According to the invention, the polydispersity index of component (b) used according to the invention also has a meaning:

Thus, it can be provided according to the invention that the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , of at least 1, in particular at least 1.1, preferably at least 1.2, preferably at least 1.3, more preferably at least 1.4.

In particular, the hyaluronic acid or the physiologically tolerable hyaluronic acid salt (component (b)) can have a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , of at most 50, in particular at most 25, preferably at most 10, preferably at most 5, more preferably at most 3, have.

Furthermore, it can be provided according to the invention that the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , in the range from 1 to 50 , in particular in the range of 1.1 to 25, preferably in the range of 1.2 to 10, preferably in the range of 1.3 to 5, particularly preferably in the range of 1.4 to 3, having.

The abovementioned molecular weights can be determined by methods which are known to the person skilled in the art. According to the invention, the number average molecular weight M _n or the weight average molecular weight M _w and / or the centrifuge average molecular weight M _z and / or the polydispersity index (PDI) of the hyaluronic acid and / or the physiologically tolerable hyaluronic acid salt (component (b)) can be determined in particular by means of gel permeation chromatography (GPC) and / or according to DIN 55672-3: 2016-03 be determined.

In addition, the number average molecular weight M _n or the weight average molecular weight M _w or the centrifuge average molecular weight M _z or the polydispersity index (PDI) of the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) can each be determined by gel permeation chromatography (GPC ), in particular at a temperature in the range from 20 ° C. to 40 ° C. and / or with 0.1 mol / l NaCl solution in deionized water as eluent and / or at a solution of hyaluronic acid and / or the physiologically acceptable hyaluronic acid Salt with a concentration of 3 g / l and / or using a dextran / pullulan standard as the calibration reagent and / or in accordance with DIN 55672-3: 2016-03.

According to the invention, it may be provided in particular that the ratio of the respective molecular weight M _n , M _w or M _z of chondroitin sulfate or of the physiologically tolerable chondroitin sulfate salt (component (a)) to the corresponding molecular weight M _n , M _w or M _z of Hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) in a range from 1: 3 to 1: 4, in particular 1: 1 to 1: 100, preferably 1: 1.5 to 1: 50, preferably 1 : 2 to 1: 25, more preferably 1: 3 to 1:10. As a result of the specific coordination of the respective molecular weights or molar masses of component (a) and component (b), particularly good results with regard to the stabilization and effective efficiency of the composition according to the invention result, in particular because - without wishing to be limited or limited to this theory - In this regard, an added effect or high compatibility of the components in question (a) and (b) with each other is present.

According to the invention, it may moreover be provided in particular that the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) is of non-animal origin.

In this context, the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) may be of bacterial or fermentative origin. In this regard, the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) may preferably be obtained by fermentation of bacteria of the genus Streptococcus, in particular Streptococcus lancefields, preferably Streptococcus lancefields strain A. The relevant extraction or isolation of the active substances is familiar to those skilled in the art, so that in this regard no further explanations are required.

Similarly, Applicants have surprisingly found that the use of a non-animal hyaluronic acid of the aforementioned kind also significantly improves the pharmaceutical efficacy of the composition of the invention with respect to the treatment of preferably inflammatory diseases of the bladder, such as cystitis, preferably interstitial cystitis is. Without wishing to be limited or limited to a specific theory, this can be justified by the fact that the non-animal, in particular bacterially obtained hyaluronic acid is a particularly pure product with defined chemical or physical properties, which is highly effective. The defined formation of the hyaluronic acid with the high purity is equally beneficial to the stability of the composition, since no impurities detrimental to the stability are present. In addition, the non-animal hyaluronic acid is well tolerated because there is no contamination or contamination with other substances, as is often the case with animal-derived products. Thus, hyaluronic acid of non-animal origin has a particularly high purity and homogeneity, which also contributes to the stability, in particular storage stability, of the composition according to the invention.

According to a preferred embodiment of the invention, the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) in the form of an alkali metal salt, preferably in the form of a sodium salt, and / or in the form of a Alkalihyaluronates. In this case, particularly good results are obtained when the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) is present in the form of sodium hyaluronate.

The component (b) of the composition according to the invention can be used in particular on the basis of a sterile or highly purified solution or suspension, in particular of the sodium salt of hyaluronic acid.

Hyaluronic acid or hyaluronic acid salt which can be used in the context of the present invention is generally available commercially, for example from Vivatis Pharma Gmbh, Hamburg (DE), Contipro SA, Dolni Dobrouc (CZ) or GFN Manufacture of Naturextrakten GmbH, Wald-Michelbach ( DE).

For further details on the concept of hyaluronic acid or its physiologically tolerated salts, RÖMPP Chemielexikon, 10th Edition, Volume 3, 1997, Georg Thieme Verlag Stuttgart / New York, page 1820, keyword: "hyaluronic acid" and reference is made to the literature cited therein, the total disclosure content of the aforementioned literature being hereby incorporated by reference in its entirety.

In general, it can be inventively provided that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) on the one hand and the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) on the other hand in the composition in a Weight ratio (concentration ratio) of component (a) on the one hand to component (b) on the other hand, [(a): (b)] in a range of 2: 1 to 1: 5, especially 1.6: 1 to 1: 4, preferably 1 , 2: 1 to 1: 3.8.

According to the invention it can also be provided that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) on the one hand and the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) on the other hand in the composition in a weight ratio (Concentration ratio) of component (a) on the one hand to component (b) on the other hand, [(a): (b)] in a range of 1: 1 to 1.6: 1, especially 1.1: 1 to 1.5: 1 , preferably 1.2: 1 to 1.4: 1, more preferably about 1.25: 1.

According to an alternative embodiment, however, it may also be provided that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) on the one hand and the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) on the other hand in the Composition in a weight ratio (concentration ratio) of component (a) on the one hand to component (b) on the other hand, [(a): (b)] in a range from 1: 3 to 1: 4, in particular 1: 3.2 to 1: 3 , 8, preferably 1: 3.4 to 1: 3.6, more preferably about 1: 3.55.

Because the Applicant has succeeded on the whole by targeted adaptation and coordination of the respective active substances on the basis of components (a) and (b) with respect to the glycosaminoglycan layer of the bladder urothelium to achieve a particularly good efficacy in the treatment of the underlying diseases, since - without wishing to be limited to a particular theory or want to set - especially in the aforementioned ratios a particularly good interaction or Integration of the active substances in the glycosaminoglycan layer of the bladder urothelium or a good regeneration of the glycosaminoglycan layer of the bladder urothelium is present, in particular in conjunction with the abovementioned specific molecular weights or molecular weights of the components (a) and (b) respectively. Consequently, as previously stated, the permeability of the urothelium is significantly decreased, which results in a significant reduction in the symptoms associated with the underlying disease, particularly cystitis, especially since irritants are no longer so deep into the urothelium or underlying layers can penetrate. The aforementioned weight ratios also have a positive effect on the stability of the composition. Likewise, due to the improved lining of the bladder wall with the reduced level of lesions and encrustations, the effectiveness of component (c) in the form of the local anesthetic at the site of action is also improved.

With regard to the local anesthetic according to component (c), the following should also be mentioned: As regards the concentration of the local anesthetic according to component (c) provided according to the invention, this can generally vary within wide ranges. However, a particularly good effectiveness has been demonstrated in the context of the present invention, when the composition of the local anesthetic (component (c)) in a concentration in a range of (0.0001 ± 0.00005) mg / ml to (100 ± 20) in particular in the range of (0.01 ± 0.005) mg / ml to (80 ± 15) mg / ml, preferably in the range of (0.1 ± 0.05) mg / ml to (75 ± 10) mg / ml, preferably in a range of (0.5 ± 0.1) mg / ml to (70 ± 5) mg / ml, preferably in a range of (1 ± 0.2) mg / ml to ( 65 ± 2) mg / ml, more preferably in a range of (5 ± 0.5) mg / ml to (60 ± 1.5) mg / ml, most preferably in a range of (10 ± 1) mg / ml ml to (50 ± 5) mg / ml, preferably about 20 mg / ml.

Similarly, it may be provided that the composition according to the invention, the local anesthetic (component (c)) in a concentration of (20 ± 19) mg / ml, in particular in a concentration of (20 ± 15) mg / ml, preferably in a Concentration of (20 ± 10) mg / ml, preferably in a concentration of (20 ± 5) mg / ml, more preferably in a concentration of about 20 mg / ml.

According to the invention it can also be provided that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) and the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) on the one hand and the local anesthetic (component (c) On the other hand, in the composition in a weight ratio (concentration ratio) of component (a) and component (b) on the one hand to component (c) on the other hand [((a) + (b)): (c)] in a range of 1: 5 to 100: 1, in particular 1: 2 to 50: 1, preferably 1: 1 to 10: 1, preferably 1.2: 1 to 5: 1, are present.

With regard to the local anesthetic used in accordance with the invention in the form of component (c), a number of locally anesthetically active substances which are well known to the person skilled in the art can be used in the context of the present invention. According to the invention, however, it is preferred if the local anesthetic (component (c)) is selected from the group of ester-type local anesthetics and amide-type local anesthetics, in particular from the group of benzocaine, procaine, tetracaine, lidocaine, etidocaine, prilocaine, mepivacaine, bupivacaine and S-Ropivacaine or salts thereof and combinations or mixtures thereof, preferably lidocaine and / or its salts.

In the context of the present invention, particularly good results are generally obtained when the local anesthetic is lidocaine or its salts, preferably lidocaine hydrochloride [IUPAC name: 2-diethylamino-N- (2,6-dimethylphenyl) acetamide]. This is a local anesthetic of the amide type, which has a good efficacy with simultaneous rapid onset of action.

According to a preferred embodiment of the invention, it is therefore provided in particular that the composition as a local anesthetic (component (c)) lidocaine or its salts, in particular Lidocainhydrochlorid contains. According to the invention, it may be provided, in particular, that the local anesthetic (component (c)) is lidocaine or its salts, in particular lidocaine hydrochloride, or that the local anesthetic (component (c)) is in the form of lidocaine and / or its salts, in particular lidocaine hydrochloride, is present.

For further information regarding lidocaine, reference may be made, for example, to RÖMPP Chemielexikon, 10th edition, volume 3, 1997, Georg Thieme Verlag Stuttgart / New York, keyword: "lidocaine" and to the literature referred to therein, the entire contents thereof is hereby incorporated by reference in its entirety. In addition, with regard to lidocaine on European Pharmacopoeia 8.0, European Directorate for the Quality of Medicines and Healthcare, pp. 2620/2621, keyword: "Lidocaine". In addition, with regard to lidocaine hydrochloride, reference may be made to European Pharmacopoeia 8.0, European Directorate for the Quality of Medicines and Healthcare, pp. 2620/2621, keyword: "Lidocaine Hydrochloride".

As stated above, lidocaine or lidocaine hydrochloride is a local anesthetic of the abovementioned amide type, which is preferably present in the composition according to the invention in protonated form, which applies in particular to the case in which the lidocaine is used in the form of lidocaine hydrochloride. As a result, the stability of the composition according to the invention is further improved and also the efficiency of action with regard to the analgesic properties continues to increase. The targeted use of lidocaine or lidocaine hydrochloride thus leads to even further improved properties with regard to the stability during storage of the composition according to the invention and with regard to an effective reduction of pain when the composition according to the invention is used.

When using the composition according to the invention a sustained reduction of the pain symptoms takes place, whereby the effect starts quickly and lasts for a long time, as stated above.

Furthermore, as regards component (d) optionally used according to the invention, the composition may comprise the buffer system, in particular the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)) in a total concentration of buffer system, in particular dihydrogenphosphate / monohydrogenphosphate buffer system (component ( d)) in the range of (0.1 ± 0.05) mg / ml to (10 ± 1) mg / ml, in particular in the range of (0.5 ± 0.05) mg / ml to (8 ± 1) mg / ml, preferably in a range of (0.75 ± 0.05) mg / ml to (5 ± 1) mg / ml, preferably in a range of (1 ± 0.05) mg / ml to ( 2 ± 1) mg / ml.

In general, the composition according to the invention may contain the dihydrogenphosphate / monohydrogen phosphate buffer system (component (d)) in a weight ratio (concentration ratio) of dihydrogenphosphate to monohydrogenphosphate [dihydrogenphosphate: monohydrogenposphate], in particular based on the initial weight in the production and / or provision of the composition, in the range from 10: 1 to 1: 100, in particular in the range from 5: 1 to 1:75, preferably in the range from 2: 1 to 1:50, preferably in the range from 1: 1 to 1:40, particularly preferably in Range of 1: 2 to 1: 30, most preferably in the range of 1: 5 to 1: 25 included.

In the context of the present invention, the targeted use of a special buffer system, in particular a chemical buffer system, according to component (d) on the basis of the dihydrogen phosphate / monohydrogen phosphate buffer system has proven to be particularly advantageous. When using this special buffer system, in particular while maintaining the appropriate concentrations of the buffer or the buffer components, an undesirable change in the pH or an undesirable degradation of the active ingredients during storage over a longer period of time is counteracted to a particular extent and is the shelf life The composition of the invention thus improved in particular.

Furthermore, as regards the component (d) used according to the invention, the composition according to a first embodiment of the invention may comprise the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) in a total concentration of dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) of ( 1.75 ± 1.65) mg / ml, especially in a total concentration of (1.75 ± 1.5) mg / ml, preferably in a total concentration of (1.75 ± 1.25) mg / ml, preferably in a total concentration of (1.75 ± 1) mg / ml, more preferably in a total concentration of (1.75 ± 0.9) mg / ml, most preferably in a total concentration of (1.75 ± 0.8) mg / ml, more preferably in a total concentration of about 1.75 mg / ml. In particular, the composition may comprise the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) in a total amount of dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) of (87.5 ± 85) mg, especially in a total amount of (87.5 ± 75) mg, preferably in a total amount of (87.5 ± 62.5) mg, preferably in a total amount of (87.5 ± 50) mg, most preferably in a total amount of (87.5 ± 45) mg, most preferably in a total amount of (87.5 ± 40) mg, even more preferably in a total amount of about 87.5 mg, especially in a volume of about 50 ml of the composition of the invention. In particular, the composition may contain the dihydrogenphosphate of the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)), in particular based on the initial weight when preparing and / or providing the composition, in a concentration of (0.2 ± 0.19) mg / ml, in particular in a concentration of (0.2 ± 0.15) mg / ml, preferably in a concentration of (0.2 ± 0.125) mg / ml, preferably in a concentration of (0.2 ± 0.1) mg / ml ml, more preferably in a concentration of about 0.2 mg / ml. Likewise, it has proved to be advantageous if the composition comprises the monohydrogenphosphate of the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)), in particular based on the initial weight during preparation and / or provision of the composition, in a concentration of (1.5 ± 1 , 4) mg / ml, in particular in a concentration of (1.5 ± 1.25) mg / ml, preferably in a concentration of (1.5 ± 1.1) mg / ml, preferably in a concentration of (1 , 5 ± 1) mg / ml, more preferably at a concentration of (1.5 ± 0.75) mg / ml, most preferably at a concentration of about 1.5 mg / ml.

According to a second embodiment of the invention, wherein the composition according to the invention, the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total concentration of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of ( 1 ± 0.95) mg / ml, in particular in a total concentration of (1 ± 0.9) mg / ml, preferably in a total concentration of (1 ± 0.8) mg / ml, preferably in a total concentration of (1 ± 0.6) mg / ml, more preferably in a total concentration of (1 ± 0.4) mg / ml, most preferably in a total concentration of (1 ± 0.2) mg / ml, even more preferably in a total concentration of about 1 mg / ml. In this connection, the composition may comprise the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total amount of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of (52.5 ± 50) mg, in particular in a total amount of (52.5 ± 45) mg, preferably in a total amount of (52.5 ± 40) mg, preferably in a total amount of (52.5 ± 35) mg, more preferably in a total amount of (52.5 ± 30) mg, most preferably in a total amount of (52.5 ± 25) mg, even more preferably in a total amount of about 52.5 mg, especially in a volume of about 50 ml of the invention Composition. The composition may be the dihydrogen phosphate of the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)), in particular based on the initial weight when preparing and / or providing the composition, in a concentration of (0.15 ± 0.14) mg / ml, in particular at a concentration of (0.15 ± 0.12) mg / ml, preferably at a concentration of (0.15 ± 0.1) mg / ml, preferably at a concentration of (0.15 ± 0.05) mg / ml, more preferably at a concentration of about 0.15 mg / ml. In addition, the composition of the invention, the monohydrogen phosphate of the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)), in particular based on the weight in preparation and / or provision of the composition, in a concentration of (1 ± 0.9) mg / ml, in particular in a concentration of (1 ± 0.8) mg / ml, preferably in a concentration of (1 ± 0.7) mg / ml, preferably in a concentration of (1 ± 0.6) mg / ml, more preferably in a concentration of (1 ± 0.5) mg / ml, most preferably at a concentration of about 1 mg / ml.

According to one embodiment of the invention, the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) may be present as an alkali metal hydrogen phosphate / alkali monohydrogen phosphate buffer system. Preferably, the alkali metal may be selected from sodium and / or potassium, especially sodium.

In addition, the dihydrogenphosphate / monohydrogenphosphate buffering system (component (d)) may be present as a sodium dihydrogenphosphate / sodium monohydrogenphosphate buffering system.

In addition, the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) can be used as a NaH ₂ (PO ₄ ) / Na ₂ H (PO ₄ ) buffer system, especially as NaH ₂ (PO ₄ ) .2H ₂ O / Na ₂ H (PO ₄ ) · 2 H ₂ O buffer system, be present or formed.

In general, the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) may be used to adjust or maintain the pH of the composition. This results in a further stabilization of the composition according to the invention, accompanied by a particularly good compatibility of the composition according to the invention in their application or application.

Phosphate buffers which can be used in the context of the present invention are generally available commercially, for example from Merck KGaA, Darmstadt (DE).

For the term of the buffer or the chemical buffer system, reference may be made in particular to RÖMPP Lexikon Chemie, 10th edition, Georg Thieme Verlag, Stuttgart / New York, Volume 5, 1998, pages 3618/3619, keyword: "buffer", and to the literature cited therein, the entire disclosure content of the aforementioned literature being hereby incorporated by reference in its entirety.

In addition to the aforementioned active substances or ingredients, the composition according to the invention according to component (e) may comprise at least one physiologically acceptable electrolyte: In this context, the composition of the electrolyte (component (e)) in a concentration of (8 ± 6) mg / ml, in particular in a concentration of (8 ± 4) mg / ml, preferably in a concentration of (8 ± 2) mg / ml, preferably in a concentration of (8 ± 1) mg / ml, most preferably in one concentration of about 8 mg / ml.

In particular, the electrolyte (component (e)) may be present in the form of an alkali salt, in particular in the form of an alkali metal chloride, preferably in the form of sodium chloride. According to the invention, it is preferred if the electrolyte (component (e)) is sodium chloride.

Electrolytes which can be used in the context of the present invention are generally available commercially, for example from Merck KGaA, Darmstadt (DE).

As a result of the use of an electrolyte possible osmotic effects in the context of application or treatment with the composition according to the invention can be kept as low as possible, which further increases the compatibility of the composition according to the invention.

In addition, as for the pH of the composition of the present invention in general, the composition may have a pH in a range of 5.5 to 8.0, more preferably in a range of 5.6 to 7.8, preferably in a range from 5.7 to 7.5, preferably in a range from 5.8 to 7.2, particularly preferably in a range from 6.0 to 7.15. In particular, the pH of the composition may be in a range of 5.5 to 8.0, more preferably in a range of 5.6 to 7.8, preferably in a range of 5.7 to 7.5, preferably in a range from 5.8 to 7.2, more preferably in a range of 6.0 to 7.15, be kept constant or adjusted. The pH may preferably be adjusted or predetermined by means of the buffer system, in particular the alkali metal hydrogen phosphate / alkali monohydrogen phosphate buffer system (component (d)).

In compliance with the abovementioned ranges of pH, undesirable degradation of the active ingredients during storage is also particularly counteracted over a relatively long period, and the shelf life of the composition according to the invention is also improved to a particular extent. The targeted adjustment of the pH in the areas provided according to the invention also results in the composition according to the invention being physiologically well tolerated and at the same time the preferably used local anesthetics, preferably of the amide type, in particular lidocaine or lidocaine hydrochloride, significantly protonated in the protonated form or composition be present, whereby the local effect of the local anesthetic is improved, and this with high stability of the composition according to the invention. In this context too, the use of a special buffer system according to component (d) of the composition according to the invention is of great importance, since in this way the pH of the composition according to the invention can be kept at least substantially stable both during storage and during application.

In the context of the present invention, the determination of the pH can be carried out by methods known per se to those skilled in the art. In particular, the determination of the pH can be based on a potentiometric analysis. The determination of the pH may preferably be carried out according to the method according to Ph. Eur. [Pharmacopoea Europaea], 9 ^th Edition (9.0), 2017, 9th Edition English, Section 2.2.3. Potentiometric determination of pH.

For further details on the concept of pH, reference may be made in particular to RÖMPP Lexikon Chemie, 10th edition, Georg Thieme Verlag, Stuttgart / New York, Volume 4, 1998, pages 3230-3232, keyword: "pH" and the literature cited therein, the entire disclosure content of the aforementioned literature being hereby incorporated by reference in its entirety.

As far as the composition according to the invention is concerned, it may have a dynamic viscosity of at least 2,000 mPas, in particular at least 4,000 mPas, preferably at least 5,000 mPas, preferably at least 5,250 mPas, at a temperature of 20 ° C. In addition, at a temperature of 20 ° C., the composition can have a dynamic viscosity of at most 7,900 mPas, in particular at most 6,900 mPas, preferably at most 6,000 mPas, preferably at most 5,750 mPas.

According to the invention, it may be provided in particular that the composition at a temperature of 20 ° C., a dynamic viscosity in the range of 2,000 mPas to 7,900 mPas, in particular in the range of 4,000 mPas to 6,900 mPas, preferably in the range of 5,000 mPas to 6,000 mPas preferred ranging from 5,250 mPas to 5,750 mPas.

Due to the viscosity provided or adjusted according to the invention, a particularly simple and less painful instillation of the composition into the bladder is ensured. Furthermore, owing to the viscosity provided according to the invention, a particularly good interaction of the active component based on the composition according to the invention with the urothelium is present, which has a positive effect on the efficacy. In addition, the targeted adjustment of the viscosity also leads to a further stabilization of the composition, in particular with regard to - without wishing to be limited or limited to this theory - the formation of a defined matrix or a defined hydrogel, which results in an improvement of the storage stability of the Accompanying composition according to the invention.

The determination of the dynamic viscosity can be carried out by methods known to those skilled in the art. In particular, the dynamic viscosity can be determined according to the method according to Ph. Eur. [Pharmacopoea Europaea], 9 ^th Edition (9.0), 2017, 9th Edition English, Section 2.2.8. "Viscosity" and Section 2.2.9. "Capillary viscometer method" to be determined.

Furthermore, the composition according to the invention may have an osmolality in the range from 150 mosmol / kg to 600 mosmol / kg, in particular in the range from 200 mosmol / kg to 550 mosmol / kg, preferably in the range from 250 mosmol / kg to 500 mosmol / kg, preferably in Range from 275 mosmol / kg to 450 mosmol / kg, more preferably in the range of 300 mosmol / kg to 400 mosmol / kg. The targeted adjustment of the osmolality also serves to further stabilize and in particular to improve the compatibility of the composition according to the invention.

The osmolality can be determined according to methods known per se to those skilled in the art. In particular, the osmolality [Pharmacopoeia Europaea] according to the method according to Ph. Eur., 9 ^th Edition (9.0), 2017, 9th Edition English, Section 2.2.35. "Osmolality", to be determined. The adjustment of the osmolality can, for example, on the basis of the aforementioned electrolyte (component (e)), for example based on alkali ions, such as sodium ions, and chloride ions, in particular by means of sodium chloride, take place.

In addition, at a temperature of 20 ° C and at a pressure of 1,013.25 mbar (atmospheric pressure), the composition may have a density in the range of 1.001 g / cm ³ to 1.5 g / cm ³ , in particular in the range of 1.005 g / cm ³ to 1.25 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.1 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.075 g / cm ³ , especially preferably in the range of 1.0075 g / cm ³ to 1.05 g / cm ³ .

In particular, at a temperature of 20 ° C and at a pressure of 1013.25 mbar (atmospheric pressure), the composition may have a relative density, based on pure water, in the range of 1.001 to 1.5, in particular in the range of 1.005 to 1.25 , preferably in the range of 1.0075 to 1.1, preferably in the range of 1.0075 to 1.075, more preferably in the range of 1.0075 to 1.05.

In the context of the present invention, the determination of the density can be carried out with methods known per se to those skilled in the art. In particular, the relative density can be determined according to the method according to Ph. Eur. [Pharmacopoea Europaea], 9 ^th Edition (9.0), 2017, 9th Edition English, Section 2.2.5. Be determined "Relative density". By the purposeful adjustment of the density, the handling and compatibility of the composition according to the invention can be further improved.

Moreover, it is preferred in the context of the present invention if the composition is present as an aqueous composition. In this context, it may be provided in particular that the composition is aqueous-based or is present in aqueous form.

In particular, the composition may be in the form of an aqueous solution or aqueous suspension, preferably in the form of an aqueous solution.

In this connection, the composition may contain water, in particular purified water. In particular, the composition may contain water as a pharmaceutically acceptable carrier (excipient). In general, therefore, the composition may be aqueous based, especially using water for injections.

As far as the amount of water used is concerned, this can vary widely. According to the invention, it is preferred if the composition according to the invention has a content of water, in particular of purified water, of at least 50% by weight, in particular at least 75% by weight, preferably at least 80% by weight, preferably at least 90% by weight. -%, particularly preferably at least 95 wt .-%, based on the composition comprises.

Water which can be used in the context of the present invention, in particular water for injection purposes, is generally available commercially, for example from Fresenius Kabi Deutschland GmbH, Bad Homburg (DE).

According to one embodiment of the invention, it may be provided that the composition according to the invention from the aforementioned components (a), (b), (c), optionally (d), optionally (e) and optionally water, in particular purified water, in particular from the aforementioned components (a), (b), (c), (d), optionally (e) and optionally water.

In addition, it can be provided according to the invention that the composition according to the invention is at least substantially free of organic solvents and / or organic dispersants, in particular alcohol-based solvents and / or alcohol-based dispersants. In particular, it may be provided according to the invention that the composition is at least substantially free of alcohols. As a result, the compatibility of the composition according to the invention is further increased.

Not least because of the high stability, in particular storage stability, of the composition according to the invention it can also be provided in the context of the present invention that the composition is at least substantially free of preservatives or at least substantially free of disinfectants. This also improves the compatibility of the composition according to the invention, since according to the invention it is possible to dispense with the use of additives which are irritating to the urothelium or the mucous membrane of the urinary bladder.

As stated above, it has been possible in the present invention to provide a composition which is also characterized by excellent stability, so that the composition can be stored over long storage periods. On this basis, application security is also increased.

In particular, the composition may be at temperatures in the range of 20 ° C to 45 ° C, at a pressure of 1013.25 mbar (atmospheric pressure) and at a relative humidity in the range of 50% to 90% at least 6 months, in particular at least 12 months, preferably at least 24 months, preferably at least 36 months, stable, in particular storage stable. In this context, the composition at the respective storage time point a total content of degradation products of components (a) and (b) of at most 5%, in particular at most 4%, preferably at most 3%, preferably at most 2%, particularly preferably at most 1%, based on the total concentration of the components (a) and (b) or the educts.

In particular, the composition may have stability, especially storage stability, under accelerated aging conditions ASTM F 1980 [ ASTM F 1980 : Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices; 2007-04] at an aging temperature of 55 ° C of at least 6 months, in particular at least 12 months, preferably at least 24 months, preferably at least 36 months. In particular, the composition in this context relative to the respective storage time a total content of degradation products of components (a) and (b) of at most 5%, in particular at most 4%, preferably at most 3%, preferably at most 2%, particularly preferably at most 1%, based to the total concentration of the components (a) and (b) or the educts.

In addition, the composition according to the invention - if present at all - can be distinguished by a low content of alkaline earth components:

According to one embodiment of the invention, the composition may have an alkaline earth salt concentration, in particular calcium salt concentration or magnesium salt concentration of at most 1 mg / ml, in particular at most 0.5 mg / ml, preferably at most 0.1 mg / ml, preferably at most 0 , 05 mg / ml, more preferably at most 0.01 mg / ml.

In the context of the present invention, moreover, the composition may be at least substantially free of alkaline earth salts, in particular at least essentially free of calcium salts and / or magnesium salts.

In general, the composition according to the invention, an alkaline earth metal concentration, in particular calcium concentration or magnesium concentration of at most 1 mg / ml, in particular at most 0.5 mg / ml, preferably at most 0.1 mg / ml, preferably at most 0.05 mg / ml, more preferably at most 0.01 mg / ml.

In particular, the composition according to the invention may be at least substantially free of alkaline earth metals, in particular at least substantially free of calcium or magnesium salts.

In addition, the composition may have a concentration of bivalent ions, in particular bivalent cations, preferably alkaline earth ions, preferably calcium ions or magnesium ions, of at most 1 mg / ml, in particular at most 0.5 mg / ml, preferably at most 0.1 mg / ml, preferably at most 0.05 mg / ml, particularly preferably at most 0.01 mg / ml.

In particular, the composition may be at least substantially free of bivalent ions, in particular bivalent cations, preferably alkaline earth ions, preferably calcium ions and / or magnesium ions.

The concept according to the invention, according to which the composition according to the invention can be at least substantially free of alkaline earth salts or alkaline earth metals, in particular in ionic form, according to the above statements, leads in particular to an interaction with components (a) and (b ) or (c) or (d), in particular with regard to avoiding unwanted complexing or the like, is reduced or prevented. Consequently, precipitation of active components or buffer components can be counteracted on this basis. In particular, on this basis, an undesirable change in the viscosity, in particular due to an uncontrolled complex formation or the like can be avoided.

According to one embodiment of the invention, the composition, in particular application, dosing and / or ready for application, with a volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, are present.

In this context, the composition, in particular application, dosing and / or ready for administration, for administration, in particular instillation into the bladder, a volume of the composition of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, be present. In particular, the composition, in particular application, dosing and / or ready for application, in particular by means of instillation into the bladder, with a volume of the composition of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, are administered.

In general, the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) mg to (1250 ± 100) mg, especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg.

In this connection, the composition according to the invention in general, in particular application, dosing and / or ready for application, for administering an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) in particular in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg, or be prepared. In particular, the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) mg to (1250 ± 100 ), especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg.

In particular, the composition, in particular application, dosing or application ready, according to a first embodiment with an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (1000 ± 100) mg, in particular (1000 ± 75) mg, preferably (1,000 ± 50) mg, preferably about 1,000 mg. The composition according to the invention may also, in particular application, dosing and / or ready for application, for administering an amount of active ingredient in chondroitin sulfate or physiologically acceptable chondroitin sulfate salt (component (a)) of (1,000 ± 100) mg, in particular (1,000 ± 75) mg, preferably (1000 ± 50) mg, preferably about 1000 mg, be present or prepared. In this context, the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (1,000 ± 100) mg, in particular (1,000 ± 75 ), preferably (1,000 ± 50) mg, preferably about 1,000 mg.

According to a second embodiment, the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (225 ± 25) mg, in particular (225 ± 15) mg, preferably (225 ± 10) mg. In this context, the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (225 ± 25) mg, in particular (225 ± 15) mg, preferably (225 ± 10) mg, be present or prepared. In particular, the composition, in particular application, dosing and / or ready for application, therefore with an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (225 ± 25) mg, in particular (225 ± 15) mg, preferably (225 ± 10) mg.

As regards component (b), the composition according to the invention, in particular application, dosing and / or ready for application, with an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in one Range of (50 ± 25) mg to (1000 ± 100) mg, especially in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg.

In this context, it may be provided according to the invention in particular that the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in one Range of (50 ± 25) mg to (1000 ± 100) mg, especially in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg, is present or prepared.

In particular, the composition in this context, in particular application, dosing and / or ready for application, with an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in a range of (50 ± 25) mg to (1,000 ± 100) mg, especially in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg.

In addition, the composition according to the invention may in this context be applied, dosed or ready for application with an amount of hyaluronic acid or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) of (800 ± 80) mg, in particular (800 ± 60) mg, preferably (800 ± 40) mg, preferably about 800 mg.

According to the invention, the composition can in particular be applied, dosed or ready for administration for administering an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) of (800 ± 80) mg, in particular (800 ± 60) mg, preferably (800 ± 40) mg, preferably about 800 mg, be present or prepared. In particular, the composition, in particular application, dosing and / or ready for application, with an amount of hyaluronic acid or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) of (800 ± 80) mg, in particular (800 ± 60 ) mg, preferably (800 ± 40) mg, preferably about 800 mg.

In addition, as far as component (c) is concerned, the composition, in particular application-, dosage- and / or application-ready, with a drug amount of local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2.500 ± 250) mg, especially in a range of (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg.

In this context, it can also be inventively provided that the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient to local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2,500 ± 250) mg, especially in a range of (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg ,

In particular, the composition, in particular application, dosing and / or ready to use, with a drug amount of local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2500 ± 250) mg, especially in one Range (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg.

Similarly, the composition, in particular application, dosing and / or ready to use, with a drug amount of local anesthetic (component (c)) of (1,000 ± 900) mg, in particular (1,000 ± 500) mg, preferably (1,000 ± 100) mg , present.

wherein the composition, in particular application, dosing and / or ready for administration, for administering an amount of active ingredient to local anesthetic (component (c)) of (1,000 ± 900) mg, in particular (1,000 ± 500) mg, preferably (1,000 ± 100) mg , present and / or prepared. In particular, the composition, in particular application, dosing and / or ready to use, with a drug amount of local anesthetic (component (c)) of (1,000 ± 900) mg, in particular (1,000 ± 500) mg, preferably (1,000 ± 100) mg , administered.

According to the invention, therefore, in a purposive manner, in particular a special and with regard to the components (a) or (b) or (c) in particular ternary composition is turned off, which also preferably ready to use with a defined volume or with defined amounts of active substance, as in each case previously defined. Because the Applicant has found in this context in a completely surprising manner that the correspondingly coordinated active ingredients with high stability of the composition according to the invention to a particularly good effectiveness in terms of the underlying diseases of the genitourinary tract, especially cystitis, preferably interstitial cystitis lead, so in this regard there is a stability or optimum of action, even with regard to a pain-therapeutic effect. In this case, the special volume, as defined above, is also of great importance, since on this basis there is an optimal adaptation of the administration variables of the composition to be administered or instilled to the pathological situation, in particular in cystitis, preferably interstitial cystitis, namely, namely Often a reduced bladder capacity or a so-called shrink bubble may be present. By administering or instillation of the underlying specific volume, the retention time and thus the retention of the composition in the urinary bladder can be increased, which further improves the effectiveness of the composition according to the invention. In this case, the composition according to the invention also has a sustained local anesthetic effect.

In the context of the present invention, it may be provided that the composition is or is present in a storage or application device, in particular in a storage or application container, in particular application, dosage or application ready.

In this context, the composition can thus be present in particular application, metered or ready for application in a storage or application device, in particular in a storage and / or application container, preferably in volume sizes and / or with a volume of the composition of (US Pat. 50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, per container or application unit (dosing unit).

In particular, in this connection, the storage or application device according to the invention may be a preferably sterile syringe, in particular an application syringe, preferably a disposable syringe, in particular with a receiving or filling volume of (50 ± 10) ml, in particular (50 ± 5) ml , preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml. In contrast, the storage or application device may also be in the form of a vial, preferably be present or trained with sterile closure, or the like.

According to the present aspect, the present invention also relates to the composition according to the invention for instillation or for preferably topical application in the urogenital region, in particular in the bladder.

In particular, the composition according to the invention can be prepared for administration or for instillation or for preferably topical administration into the genitourinary tract, in particular into the bladder. Similarly, the composition according to the invention in this context by instillation or for preferably topical application in the genitourinary tract, especially in the bladder, administered.

Likewise, the present invention also relates to the composition according to the invention for use in the prophylactic or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the bladder, preferably of cystitis, especially acute or chronic cystitis, preferably interstitial cystitis, radiogenic cystitis, chronic recurrent cystitis, chemocystitis, chronic abacterial cystitis and chronic bacterial cystitis, especially preferred interstitial cystitis.

Likewise, the present invention also relates to the composition according to the invention for the prophylactic or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the bladder, preferably of cystitis, especially acute or chronic cystitis, preferably interstitial cystitis, radiogenic cystitis, chronic recurrent cystitis, Chemocystitis, chronic abacterial cystitis and chronic bacterial cystitis, especially preferred interstitial cystitis.

The present invention furthermore relates, according to a further aspect of the present invention, also to the use of the composition according to the invention as defined above for the prophylactic or therapeutic treatment of preferably inflammatory diseases of the urogenital tract, in particular of inflammatory diseases of the urinary bladder, preferably of cystitis, in particular acute or chronic cystitis, preferably interstitial cystitis, radiogenic cystitis, chronic recurrent cystitis, chemocystitis, chronic abacterial cystitis, and chronic bacterial cystitis, most preferably interstitial cystitis.

In this context, the present invention equally also relates to the use of the composition according to the invention, as defined above, for the preparation of a medicament or medicament for the prophylactic or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the bladder, preferably of cystitis, especially acute or chronic cystitis, preferably interstitial cystitis, radiogenic cystitis, chronic recurrent cystitis, chemocystitis, chronic abacterial cystitis and chronic bacterial cystitis, most preferably interstitial cystitis.

The composition or combination according to the invention, which chondroitin sulfate or a physiologically acceptable chondroitin sulfate salt (component (a)) and hyaluronic acid or a physiologically acceptable hyaluronic acid salt (component (b)) on the one hand and at least one local anesthetic, in particular Lidocain or Lidocainhydrochlorid , (Component (c)) on the other hand, and optionally also contains a special (phosphate) buffer system (component (d)), in the context of the uses of the invention surprisingly found on the surprisingly found high stability, especially storage stability, also to a particularly good activity with regard to the underlying diseases, while also ensuring a sustained and rapid onset of pain reduction, as previously stated.

For purposes of the uses according to the invention, the composition according to the invention can be instilled or applied topically in the urogenital region, in particular in the urinary bladder. In this case, the instillation or the application should take place in the preferably previously emptied bladder. In this regard, the composition of the invention may remain in the urinary bladder, for example, for a period of several minutes to a few hours, to allow for optimal action of the drugs on the urothelium. By the inventively provided composition thereby a particularly efficient interaction of the present in particular in specific amounts or doses of active ingredients in the form of components (a) or (b) with the urothelium is possible, along with a correspondingly high arrival or storage of in Talking drugs on or in the underlying layer of the bladder. In addition, the local anesthetic (component (c)) can optimally unfold its effect on this basis.

In this context, it is possible in particular to proceed in such a way that the underlying volume of the composition, which is in particular in the storage or application device described below, is instilled after complete emptying of the urinary bladder into the bladder, wherein the underlying volume is in particular about 50 ml should be. For optimum results, the composition according to the invention should remain in the urinary bladder for as long as possible, as described above, for a period of several minutes to several hours.

For example, in the context of the treatment of cystitis or interstitial cystitis, it is possible to carry out the instillation of the composition according to the invention for a period of four weeks, once a week, with the respective single dose of chondroitin sulfate or component (a), for example, about 1,000 mg or but for example about 225 mg, the single dose of hyaluronic acid or component (b) should be, for example, about 800 mg and the single dose of local anesthetic or component (c) in a volume of the composition should be about 50 ml. As part of a maintenance therapy, the composition according to the invention can then be applied, for example, once a month, in particular until the symptoms have completely subsided. However, it is also possible to deviate from the aforementioned exemplary therapy scheme if required in a given case.

A further advantage of the inventive uses of the composition according to the invention is also to be seen in the fact that it is safe in terms of their application and during treatment generally no significant side effects occur, especially since it is not least based on the active components ( a) and (b) are biocompatible substances. The particularly good compatibility is associated in particular with the use of chondroitin sulfate of marine origin or hyaluronic acid of non-animal origin. In addition, the local anesthetics used according to the invention, in particular with regard to lidocaine or lidocaine hydrochloride, also have good compatibility.

By the purposeful use of the abovementioned special doses or active ingredient amounts of the components (a), (b) or (c), furthermore, the high activity of the composition according to the invention is further optimized which, moreover, is not adversely affected by the buffer system optionally provided according to the invention. On the contrary, the targeted use of the buffer system according to component (d) in combination with the further measures according to the invention leads to an effective stabilization of the composition, which likewise leads to a high degree of application safety and maintenance of the effectiveness or effective efficiency.

In summary, the composition according to the invention is preferably a medical product which, according to one embodiment of the invention, contains or represents a specially dosed solution or dispersion of the active ingredients based on components (a) and (b) and component (c).

In general, the composition can be used at least once a week, preferably over a period of preferably at least one month, be administered by instillation or for topical application in the bladder.

As regards the composition according to the invention as such or its uses in general, the composition may in particular have a volume of the composition of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml ( 50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, and / or an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of ( 100 ± 25) mg to (1250 ± 100) mg, especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg , and / or an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in a range of (50 ± 25) mg to (1000 ± 100) mg, in particular in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to ( 800 ± 100) mg, and / or an amount of active local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2500 ± 250) mg, especially in a range of (10 ± 1) mg bis (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg, especially at least once a week, preferably over a period of preferably at least one month, administered to the bladder and / or instilled and / or preferably administered topically or at least weekly administration (at least once a week), preferably over a period of preferably at least one month, prepared by instillation and / or topical application in the bladder or the composition can at least once per week, preferably over a period of preferably at least one month, be administered by instillation and / or for topical application in the bladder.

For further details on the uses of the composition according to the invention, reference may be made to the statements on the other aspects of the invention, which apply correspondingly with respect to the uses according to the invention.

The composition of the invention is also characterized in this context by an excellent storage stability and high efficiency, along with a sustained analgesic effect, as stated above.

According to yet another aspect of the present invention, the present invention equally relates to a storage or application device, in particular a storage or application container, in particular in the form of a preferably sterile syringe, in particular syringe, preferably disposable syringe, preferably for instillation or for preferably topical application in the urogenital area, in particular in the urinary bladder, containing a composition according to the invention, as defined above.

1. (a) Chondroitinsulfat und/oder ein physiologisch verträgliches Chondroitinsulfat-Salz (Komponente (a));
2. (b) Hyaluronsäure und/oder ein physiologisch verträgliches Hyaluronsäure-Salz (Hyaluronat) (Komponente (b)); und
3. (c) mindestens ein Lokalanästhetikum (Komponente (c));

enthält.In this context, the present invention according to this aspect also relates to a storage or application device, in particular a storage container or application container, in particular in the form of a preferably sterile syringe, in particular syringe, preferably disposable syringe, preferably for instillation or preferably topical Application in the urogenital region, in particular in the bladder, containing a composition, in particular as defined above,
wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts

1. (a) chondroitin sulfate and / or a physiologically acceptable chondroitin sulfate salt (component (a));
2. (b) hyaluronic acid and / or a physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)); and
3. (c) at least one local anesthetic (component (c));

contains.

In particular, the composition may also contain (d) a buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)).

In addition, the composition may also contain (e) at least one physiologically acceptable electrolyte (component (e)).

According to the invention, it is preferred if the storage or application device has a receiving or filling volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml , more preferably (50 ± 0.5) ml, most preferably about 50 ml.

In particular, the composition may contain an amount of active ingredient of (a) chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) mg to (1250 ± 100) mg, especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg.

In addition, the composition may contain an amount of active ingredient of (b) hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in a range of (50 ± 25) mg to (1000 ± 100) mg, especially in one range from (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg.

Furthermore, the composition according to the invention may contain an amount of active ingredient of (c) local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2.500 ± 250) mg, especially in a range of (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg.

According to the invention, it can also be provided according to a first embodiment that the composition comprises the buffer system, in particular the dihydrogenphosphate / monohydrogenphosphate buffer system, (component (d)) in a total amount of buffer system, in particular dihydrogenphosphate / monohydrogenphosphate buffer system, (component (d) ) of (87.5 ± 85) mg, especially in a total amount of (87.5 ± 75) mg, preferably in a total amount of (87.5 ± 62.5) mg, preferably in a total amount of (87.5 ± 50) mg, more preferably in a total amount of (87.5 ± 45) mg, most preferably in a total amount of (87.5 ± 40) mg, even more preferably in a total amount of about 87.5 mg ,

According to the invention, it can also be provided according to a second embodiment that the composition comprises the buffer system, in particular the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)) in a total amount of buffer system, in particular dihydrogenphosphate / monohydrogenphosphate buffer system, (component (d) ) of (52.5 ± 50) mg, especially in a total amount of (52.5 ± 45) mg, preferably in a total amount of (52.5 ± 40) mg, preferably in a total amount of (52.5 ± 30 ), more preferably in a total amount of (52.5 ± 25) mg, most preferably in a total amount of (52.5 ± 20) mg, even more preferably in a total amount of about 52.5 mg.

In particular, the composition may be added to the electrolyte (component (e)) in an amount of (400 ± 300) mg, especially in an amount of (400 ± 200) mg, preferably in an amount of (400 ± 100) mg, preferably in one Amount of (400 ± 50) mg, more preferably in an amount of about 400 mg.

According to the invention, it can also be provided that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) is present in the form of an alkali metal salt, preferably in the form of a sodium salt.

Similarly, it may be provided according to the invention that the chondroitin sulfate or the physiologically acceptable chondroitin sulfate salt (component (a)) in the form of chondroitin sulfate sodium (sodium chondroitin sulfate) is present.

In addition, the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) may be in the form of an alkali metal salt, preferably in the form of a sodium salt, and / or in the form of an alkali hyaluronate.

In particular, the hyaluronic acid or the physiologically acceptable hyaluronic acid salt (component (b)) may be present in the form of sodium hyaluronate.

Furthermore, the local anesthetic (component (c)) may be selected from the group of ester-type local anesthetics and amide-type local anesthetics, in particular from the group of benzocaine, procaine, tetracaine, lidocaine, etidocaine, prilocaine, mepivacaine, bupivacaine and s-ropivacaine or theirs Salts and their combinations or mixtures, preferably lidocaine and / or its salts.

According to the invention it can be provided in particular that the composition contains as local anesthetic (component (c)) lidocaine and / or its salts, in particular Lidocainhydrochlorid. In particular, the local anesthetic (component (c)) may thus be lidocaine and / or its salts, in particular lidocaine hydrochloride, and / or in the form of lidocaine and / or its salts, in particular lidocaine hydrochloride.

In addition, the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) may be present as an alkali metal hydrogen phosphate / alkali monohydrogen phosphate buffer system. In this connection, the alkali metal may be selected from sodium and / or potassium, especially sodium.

In particular, the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) may be present as a sodium dihydrogen phosphate / sodium monohydrogen phosphate backbone system.

In addition, the electrolyte (component (e)) may be in the form of an alkali salt, in particular in the form of an alkali metal chloride, preferably in the form of sodium chloride. In particular, the electrolyte (component (e)) may be sodium chloride.

Further, as for the composition, it may have a pH in a range of 5.5 to 8.0, more preferably in a range of 5.6 to 7.8, preferably in a range of 5.7 to 7.5 , preferably in a range from 5.8 to 7.2, more preferably in a range from 6.0 to 7.15.

In particular, the pH of the composition may be in a range of 5.5 to 8.0, more preferably in a range of 5.6 to 7.8, preferably in a range of 5.7 to 7.5, preferably in a range from 5.8 to 7.2, more preferably in a range of 6.0 to 7.15, be kept constant or adjusted.

The pH may preferably be adjusted or predetermined by means of the buffer system, in particular the alkali metal hydrogen phosphate / alkali monohydrogen phosphate buffer system (component (d)).

In particular, the composition may have at a temperature of 20 ° C. a dynamic viscosity of at least 2,000 mPas, in particular at least 4,000 mPas, preferably at least 5,000 mPas, preferably at least 5,250 mPas.

Likewise, at a temperature of 20 ° C., the composition can have a dynamic viscosity of at most 7,900 mPas, in particular at most 6,900 mPas, preferably at most 6,000 mPas, preferably at most 5,750 mPas.

In addition, at a temperature of 20 ° C., the composition can have a dynamic viscosity in the range from 2,000 mPas to 7,900 mPas, in particular in the range from 4,000 mPas to 6,900 mPas, preferably in the range from 5,000 mPas to 6,000 mPas, preferably in the range from 5,250 mPas to 5,750 mPas.

Furthermore, the composition may have an osmolality in the range of 150 mosmol / kg to 600 mosmol / kg, in particular in the range of 200 mosmol / kg to 550 mosmol / kg, preferably in the range of 250 mosmol / kg to 500 mosmol / kg, preferably in the range from 275 mosmol / kg to 450 mosmol / kg, more preferably in the range of 300 mosmol / kg to 400 mosmol / kg.

Furthermore, the composition at a temperature of 20 ° C and at a pressure of 1013.25 mbar (atmospheric pressure), a density in the range of 1.001 g / cm ³ to 1.5 g / cm ³ , in particular in the range of 1.005 g / cm ³ to 1.25 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.1 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.075 g / cm ³ , more preferably in the range of 1.0075 g / cm ³ to 1.05 g / cm ³ .

In particular, at a temperature of 20 ° C and at a pressure of 1013.25 mbar (atmospheric pressure), the composition may have a relative density, based on pure water, in the range of 1.001 to 1.5, in particular in the range of 1.005 to 1.25 , preferably in the range of 1.0075 to 1.1, preferably in the range of 1.0075 to 1.075, more preferably in the range of 1.0075 to 1.05.

According to the invention it is preferred if the storage or application device, the composition, in particular application, dosing and / or ready for application, with a volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2 ) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml.

In particular, the composition may have a volume of (50 ± 10) ml, especially (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, most preferably (50 ± 0.5) ml, most preferably about 50 ml are present.

In addition, it is preferred according to the invention if the composition is present as an aqueous composition. In particular, the composition may in particular be aqueous-based or be in aqueous form, in particular in the form of an aqueous solution or aqueous suspension, preferably in the form of an aqueous solution.

In particular, the composition may contain water, especially purified water. In particular, the composition may contain water as a pharmaceutically acceptable carrier (excipient). According to the invention, the composition may be formed aqueous based. In this context, the composition may have a water content of at least 50% by weight, in particular at least 75% by weight, preferably at least 80% by weight, preferably at least 90% by weight, particularly preferably at least 95% by weight. , based on the composition.

According to the invention, the composition provided for the storage or application device according to the invention can be prepared from the abovementioned components (a), (b), (c), optionally (d), optionally (e) and optionally water, in particular from the abovementioned components ( a), (b), (c) and optionally (d) and optionally water.

For further details regarding the storage or application device according to the invention, which contains the composition according to the invention, reference may also be made to the comments on the other aspects of the invention, which apply correspondingly with respect to the storage or application device according to the invention.

Moreover, the present invention - according to yet another aspect of the present invention - also relates to the packaging unit according to the invention, which contains at least one storage or application device, as defined above. In this context, the storage or application device may be present in an outer packaging that protects against contamination. For further details of the packaging unit according to the invention, reference may be made to the remarks on the other aspects of the invention, which apply correspondingly in relation to the packaging unit according to the invention.

Finally, according to a further aspect of the present invention, the present invention also relates to the kit according to the invention, in particular instillation system comprising (i) at least one storage or application device as defined above, and (ii) at least one composition as defined above, in particular wherein the composition is preferably present in the storage and / or application device ready for application, dosing or application, and (iii) at least one instillation device connectable to the storage or application device, in particular in the form of an instillation tube or the like.

For further details on the kit according to the invention, reference may be made to the preceding remarks on the other aspects of the invention, which apply correspondingly in relation to the kit according to the invention.

As far as the prophylactic or therapeutic treatment of the inflammatory diseases of the urogenital tract, in particular inflammatory diseases of the urinary bladder, preferably of cystitis, particularly preferably of interstitial cystitis, is concerned, this may in particular also be symptomatic or topical (local ) Pain treatment and / or pain therapy, in particular as regards the reduction of pain in the area of the genitourinary tract or the bladder. Thus, according to the invention, in view of the underlying and often associated with sometimes severe pain, such as cystitis, most preferably interstitial cystitis, an effective pain therapy concept is equally provided in which in addition to the bladder mucosal repair associated with the administration, pain associated with the disorder is also effective can be treated.

In the context of the present invention, therefore, based on the composition according to the invention, a powerful overall concept for the treatment of preferably inflammatory diseases of the genitourinary tract, such as cystitis, preferably interstitial cystitis, is provided, according to which the composition according to the invention, in addition to its high basic activity, also has improved analgesic properties and also lower analgesic properties Side effects at the same time excellent handling and high stability, in particular storage stability, has.

Further embodiments, modifications and variations as well as advantages of the present invention will be readily apparent to and realizable by those skilled in the art upon reading the description without departing from the scope of the present invention.

The following embodiments are merely illustrative of the present invention without, however, limiting the present invention thereto.

EMBODIMENTS

Preparation Examples

To prepare each 50 ml of a clear, optionally slightly yellowish colored aqueous solution of inventive compositions, the procedure is carried out in a manner known per se to those skilled in the art.

First, a defined subset (in particular about 75% of the desired final volume) of purified water is initially introduced at room temperature and ambient pressure in a glass vessel with stirrer. With stirring, first an electrolyte in the form of sodium chloride and subsequently the components of the buffer system in the form of sodium dihydrogen phosphate and disodium hydrogen phosphate are added. After complete dissolution of the components, the pH is determined and adjusted to the desired value (for example pH of about 6.5), if appropriate using phosphoric acid and / or sodium hydroxide solution.

Subsequently, the following quantities and types of further active ingredients and ingredients specified in the formulation examples are added with stirring, component (a) in the form of chondroitin sulfate salt (chondroitin sulfate sodium), component (b) in the form of sodium hyaluronate and component ( c) in the form of lidocaine hydrochloride. The solution is made up to the desired final volume of 50 ml with further water.

Subsequently, the pH of the composition obtained is determined again and optionally readjusted. The other corresponding specifications of the solutions are also checked for the set or preselected value ranges (eg osmolality, relative density, microbiological purity and sterility, exclusion of impurities, in particular decomposition products of the ingredients and active substances, viscosity, appearance).

The solution thus obtained can then be subjected to sterile filtration, for example with the aid of nitrogen via a filter candle with a special filter system, and subsequently into a particularly sterile receiving or application container, such as a plastic syringe or the like, filled. The resulting composition can be used for further stability studies or for appropriate application or efficacy studies.

According to this general preparation specification, the formulations or compositions specified below are prepared by dissolving in water the following components with the appropriate amounts (initial weight during preparation of the composition).

A first series (series I) of compositions based on higher amounts of chondroitin sulfate and a second series (series II) of compositions based on lower amounts of chondroitin sulfate are prepared:

Series I:

Compositions A1, B1 to B8, C1 and C2, D1 and D2, E1 to E5 and F1 to F4

Composition A1 (per 50 ml composition) ingredient Amount / mg quality Chondroitin sulfate sodium 1000 Ph. Eur. M _n = 15 kDa; M _w = 100 kDa; M _z = 430 kDa sodium hyaluronate 800 Ph. Eur. M _n = 55 kDa; M _w = 200 kDa; M _z = 700 kDa lidocaine 1000 Ph. Eur. Buffer system: Ph. Eur. sodium 11 (NaH ₂ (PO ₄ ) .2H ₂ O) / disodium 76 (Na ₂ H (PO ₄ ) .2H ₂ O) electrolyte 395 Ph. Eur. (Sodium chloride) Purified water ad 50 ml Ph. Eur.

The pH of composition A1 is also about 6.5.

Compositions B1 to B4

Other compositions are prepared according to composition A1 but with the proviso that different amounts of chondroitin sulfate sodium are used: composition Amount of chondroitin sulfate sodium / mg Composition B1 850 Composition B2 900 Composition B3 1100 Composition B4 1150

Compositions B5 to B8

Further compositions are prepared according to composition A1, but with the proviso that different amounts of sodium hyaluronate are used: composition Amount of sodium hyaluronate / mg Composition B5 720 Composition B6 680 Composition B7 880 Composition B8 940

Compositions C1 and C2

Further compositions are prepared according to composition A1, but with the proviso that the chondroitin sulfate sodium (CS-Na) is used at a respective amount of 1,000 mg each with different molecular weights: composition CS-Na CS-Na CS-Na M _n M _w M _z Composition C1 1 kDa 5 kDa 50 kDa Composition C2 35 kDa 250 kDa 1,100 kDa

Compositions D1 and D2

Again further compositions correspond to the composition A1, but with the proviso that that of sodium ethyluronate (HA-Na) is used in an amount thereof in each case of 800 mg with different molecular weights: composition HA-Na HA-Na HA-Na M _n M _w M _z Composition D1 2 kDa 4 kDa 275 kDa Composition D2 275 kDa 325 kDa 1,750 kDa

Compositions E1 to E5

In still further compositions based on composition A1, the pH is varied as follows: composition PH value Composition E1 5.50 Composition E2 6.00 Composition E3 7.15 Composition E4 7.50 Composition E5 8.00

Compositions F1 to F4

In still other compositions, the buffer system is varied; For this purpose, correlating amounts of buffer systems based on carbonic acid / bicarbonate, acetic acid / acetate, carbonic acid / silicate and citric acid / citrate are used for the phosphate buffer system used in composition A1; the compositions F1 to F4 thus correspond to composition A1 with the proviso that in this regard a different type of buffer system is used: composition buffer system Composition F1 Carbonic acid / bicarbonate Composition F2 Acetic acid / acetate Composition F3 Carbonic acid / silicate Composition F4 Citric acid / citrate

Series II:

Compositions A1 ', B1' to B8 ', C1' and C2 ', D1' and D2 ', E1' to E5 'and F1' to F4 '

Composition A1 '(data per 50 ml composition) ingredient Amount / mg quality Chondroitin sulfate sodium 225 Ph. Eur. M _n = 15 kDa; M _w = 100 kDa; M _z = 430 kDa sodium hyaluronate 800 Ph. Eur. M _n = 55 kDa; M _w = 200 kDa; M _z = 700 kDa lidocaine 1000 Ph. Eur. Buffer system: Ph. Eur. sodium 11 (NaH ₂ (PO ₄ ) .2H ₂ O) / disodium 76 (Na ₂ H (PO ₄ ) .2H ₂ O) electrolyte 395 Ph. Eur. (Sodium chloride) Purified water ad 50 ml Ph. Eur.

The pH of the composition A1 'is also about 6.5.

Compositions B1 'to B4'

Other compositions are prepared according to composition A1 ', but with the proviso that different amounts of chondroitin sulfate sodium are used: composition Amount of chondroitin sulfate sodium / mg Composition B1 ' 150 Composition B2 ' 200 Composition B3 ' 250 Composition B4 ' 300

Compositions B5 'to B8'

Additional compositions are prepared according to composition A1 ', but with the proviso that different amounts of sodium hyaluronate are used: composition Amount of sodium hyaluronate / mg Composition B5 ' 720 Composition B6 ' 680 Composition B7 ' 880 Composition B8 ' 940

Compositions C1 'and C2'

Additional compositions according to the composition A1 'are again prepared, but with the proviso that the chondroitin sulfate sodium (CS-Na) is used with an amount of 225 mg of different molecular weights used in each case: composition CS-Na CS-Na CS-Na M _n M _w M _z Composition C1 ' 1 kDa 5 kDa 50 kDa Composition C2 ' 35 kDa 250 kDa 1,100 kDa

Compositions D1 'and D2'

Again further compositions correspond to the composition A1 ', but with the proviso that that of sodium ethyluronate (HA-Na) is used at an amount thereof in each case of 800 mg with different molecular weights: composition HA-Na HA-Na HA-Na M _n M _w M _z Composition D1 ' 2 kDa 4 kDa 275 kDa Composition D2 ' 275 kDa 325 kDa 1,750 kDa

Compositions E1 'to E5'

In still other compositions based on composition A1 ', the pH is varied as follows: composition PH value Composition E1 ' 5.50 Composition E2 ' 6.00 Composition E3 ' 7.15 Composition E4 ' 7.50 Composition E5 ' 8.00

Compositions F1 'to F4'

In still other compositions, the buffer system is varied; For this purpose, correlating amounts of buffer systems based on carbonic acid / bicarbonate, acetic acid / acetate, carbonic acid / silicate and citric acid / citrate are used for the phosphate buffer system used in composition A1 '; the compositions F1 'to F4' thus correspond to composition A1 'with the proviso that in this regard a different type of buffer system is used: composition buffer system Composition F1 ' Carbonic acid / bicarbonate Composition F2 ' Acetic acid / acetate Composition F3 ' Carbonic acid / silicate Composition F4 ' Citric acid / citrate

stability studies

Stability tests are carried out on respective batches of the compositions according to series I) and series II) according to the formulations described above.

For this purpose, at respective storage times or on the one hand, the total content of degradation products of the components used in the listed compositions, determined, respectively at the beginning of the investigations and with corresponding storage times of 3 months, 6 months, 12 months, 18 months , 24 months, 36 months and 39 months. On the other hand, over the same storage period to the aforementioned storage times, a determination of the pH and the viscosity.

The storage is carried out for a first batch of the compositions according to series I) or series II) at a temperature of (25 ± 2) ° C and at a relative humidity of the environment of (60 ± 5)% r.H. (following Tables 1A to 1F (Series I) and 1A 'to 1F' (Series II)).

In addition, for a further batch of the compositions, storage at a temperature of (40 ± 2) ° C and at a relative humidity of the environment of (75 ± 5)% r.H. (Tables 2A to 2F (Series I) and 2A 'to 2F' (Series II) below).

The following Tables 1A to 1F and 2A to 2F (Series I) and 1A 'to 1F' and 2A 'to 2F' (Series II) show the results obtained in this respect.

In the tables below, "++" means a total content of degradation products ("degradation") at the respective storage time of at most 3%, based on the total concentration of the components, or a change in the pH value ("pH") or the viscosity ("Viscous") at the respective storage time of not more than 3%, based on the respective initial value. Furthermore, "+" means a total content of degradation products for each Storage time of at most 5%, based on the total concentration of the components, or a change in the pH or the viscosity at the respective storage time of not more than 5%, based on the respective initial value. Finally, "-" means a total content of decomposition products at the respective storage time of more than 5%, based on the total concentration of the components, or a change in pH or viscosity at the respective storage time of more than 5%, based on the respective baseline.

Series I:

Table 1A [(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m A1 reduction ++ ++ ++ ++ ++ ++ ++ pH ++ ++ ++ ++ ++ ++ ++ visco ++ ++ ++ ++ ++ ++ ++ Table 1B [(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m B1 reduction ++ ++ ++ + + + + pH ++ ++ ++ ++ + + + visco ++ ++ ++ ++ + + + B2 reduction ++ ++ ++ ++ ++ + + pH ++ ++ ++ ++ ++ ++ + visco ++ ++ ++ ++ ++ + + B3 reduction ++ ++ ++ ++ ++ ++ + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ + + + + B4 reduction ++ ++ ++ ++ + + + pH ++ ++ ++ + + + + visco ++ ++ ++ + + + + 3 m 6 m 12 m 18 m 24 m 36 m 39 m B5 reduction ++ ++ ++ ++ + + + pH ++ ++ ++ + + + + visco ++ ++ ++ + + + + B6 reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ ++ ++ + + B7 reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ ++ + + + B8 reduction ++ ++ ++ + + + + pH ++ ++ ++ + + + + visco ++ ++ ++ + + + + Table 1C [(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m C1 reduction ++ ++ + + + + + pH ++ ++ ++ + + + + visco ++ ++ ++ + + + + C2 reduction ++ ++ ++ ++ + + + pH ++ ++ ++ + + + + visco ++ ++ ++ ++ + + + Table 1D [(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m D1 reduction ++ ++ ++ + + + + pH ++ ++ ++ + + + + visco ++ ++ + + + + + D2 reduction ++ ++ + + + + + pH ++ ++ ++ + + + + visco ++ ++ ++ + + + + Table 1E [(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m E1 reduction ++ ++ ++ + + + + pH ++ ++ + + + + + visco ++ ++ + + + + - E2 reduction ++ ++ ++ ++ ++ ++ + pH ++ ++ ++ ++ ++ ++ + visco ++ ++ ++ ++ ++ + + E3 reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ ++ + + + E4 reduction ++ ++ + + + + - pH ++ ++ ++ + + + - visco ++ ++ + + + + + E5 reduction ++ ++ + + + + - pH ++ ++ + + + + - visco ++ ++ + + + + - Table 1F [(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m F1 reduction ++ ++ + - - - - pH ++ ++ + + + - - visco ++ ++ + + - - - F2 reduction ++ ++ + + - - - pH ++ ++ + + + - - visco ++ ++ + + + - - F3 reduction ++ ++ + + - - - pH ++ ++ + + - - - visco ++ ++ + + + - - F4 reduction ++ ++ + + + - - pH ++ ++ + + + - - visco ++ ++ + + + - - Table 2A [(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m A1 reduction ++ ++ ++ ++ ++ + + pH ++ ++ ++ ++ + + + visco ++ ++ ++ ++ ++ + + Table 2B [(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m B1 reduction ++ ++ ++ + + + - pH ++ ++ + + + + - visco ++ ++ + + + + - B2 reduction ++ ++ ++ ++ + + - pH ++ ++ ++ ++ + + + visco ++ ++ ++ + + + + B3 reduction ++ ++ ++ + + + + pH ++ ++ ++ + + + + visco ++ ++ + + + + + B4 reduction ++ ++ + + + - - pH ++ ++ + ++ + + - visco ++ + + + + - - B5 reduction ++ ++ + + + - - pH ++ ++ ++ + + - - visco ++ ++ ++ + + - - B6 reduction ++ ++ ++ + + + - pH ++ ++ ++ ++ ++ + - visco ++ ++ ++ ++ ++ + - B7 reduction ++ ++ ++ ++ + + - pH ++ ++ ++ ++ + + - visco ++ ++ ++ + + - - B8 reduction ++ + + + - - - pH ++ ++ + + + - - visco ++ ++ ++ + + - - Table 2C [(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m C1 reduction ++ ++ ++ + + + + pH ++ ++ + + + + - visco ++ + + + + + - C2 reduction ++ ++ + + + - - pH ++ ++ ++ + + + - visco ++ ++ + + + - - Table 2D [(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m D1 reduction ++ ++ + + + + - pH ++ ++ + + + + + visco ++ + + + + + - D2 reduction ++ ++ + + + + - pH ++ ++ + + + + - visco ++ + + + - - - Table 2E [(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m E1 reduction + + + - - - - pH ++ + + + + - - visco ++ + + + + - - E2 reduction ++ ++ ++ + + + - pH ++ ++ ++ + + + + visco ++ ++ ++ + + + - E3 reduction ++ ++ ++ + + - - pH ++ ++ ++ + + + + visco ++ ++ ++ + + - - E4 reduction ++ + + + + + - pH ++ ++ + + + - - visco ++ + + + + - - E5 reduction ++ ++ + + + - - pH ++ ++ ++ + - - - visco ++ ++ + + + - - Table 2F [(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m F1 reduction ++ + - - - - - pH ++ + + - - - - visco ++ + + - - - - F2 reduction ++ + + - - - - pH ++ + + + - - - visco ++ + + + - - - F3 reduction + - - - - - - pH ++ + - - - - - visco + + - - - - - F4 reduction ++ + + - - - - pH ++ ++ + + - - - visco ++ + + - - - -

Series II:

Table 1A '[(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6M 12 m 18 m 24 m 36 m 39 m A1 ' reduction ++ ++ ++ ++ ++ ++ ++ pH ++ ++ ++ ++ ++ ++ ++ visco ++ ++ ++ ++ ++ ++ ++ Table 1B '[(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m B1 ' reduction ++ ++ ++ + + + - pH ++ ++ ++ + + + + visco ++ ++ ++ ++ + + + B2 ' reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ ++ ++ + visco ++ ++ ++ ++ ++ + + B3 ' reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ + + + + B4 ' reduction ++ ++ ++ + + + - pH ++ ++ ++ + + + + visco ++ ++ ++ + + + - 3 m 6 m 12 m 18 m 24 m 36 m 39 m B5 ' reduction ++ ++ ++ + + + - pH ++ ++ ++ + + + + visco ++ ++ ++ ++ + + + B6 ' reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ + + + visco ++ ++ ++ ++ ++ + + B7 ' reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ ++ ++ + visco ++ ++ ++ + + + + B8 ' reduction ++ ++ ++ + + + - pH ++ ++ + + + + + visco ++ ++ ++ + + + + Table 1C '[(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m C1 ' reduction ++ ++ + + + + + pH ++ ++ ++ + + + + visco ++ ++ + + + + + C2 ' reduction ++ ++ + + + + + pH ++ ++ ++ + + + + visco ++ ++ ++ ++ + + + Table 1D '[(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m D1 ' reduction ++ ++ + + + + + pH ++ ++ ++ + + + + visco ++ ++ + + + + - D2 ' reduction ++ ++ + + + + + pH ++ ++ ++ + + + + visco ++ ++ ++ + + + + Table 1E '[(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m E1 ' reduction + + + + - - - pH ++ + + + + + - visco ++ ++ + + + - - E2 ' reduction ++ ++ ++ ++ ++ + + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ ++ ++ + + E3 ' reduction ++ ++ ++ ++ + + + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ + + + + E4 ' reduction ++ + + + + - - pH ++ + + + + + - visco ++ + + + + + - E5 ' reduction ++ ++ + + + - - pH ++ ++ ++ + + + - visco ++ ++ + + + + - Table 1F '[(25 ± 2) ° C and (60 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m F1 ' reduction + + + - - - - pH ++ + + + + - - visco ++ + + - - - - F2 ' reduction ++ + + - - - - pH ++ ++ + + + - - visco ++ + + + + - - F3 ' reduction ++ + + + - - - pH + + + + - - - visco ++ ++ + + + - - F4 ' reduction ++ ++ + + + - - pH ++ ++ + + + - - visco ++ ++ + + + - - Table 2A '[(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m A1 ' reduction ++ ++ ++ ++ ++ ++ + pH ++ ++ ++ ++ ++ + + visco ++ ++ ++ ++ + + + Table 2B '[(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m B1 ' reduction ++ ++ + + + - - pH ++ ++ + + + + - visco ++ ++ + + + + - B2 ' reduction ++ ++ + + + + - pH ++ ++ ++ + + + + visco ++ ++ ++ + + + + B3 ' reduction ++ ++ ++ + + + + pH ++ ++ + + + + + visco ++ ++ + + + + + B4 ' reduction ++ ++ + + + - - pH ++ ++ + + + - - visco ++ + + + + - - B5 ' reduction ++ + + + - - - pH ++ ++ ++ + + - - visco ++ ++ ++ + + - - B6 ' reduction ++ ++ ++ + + - - pH ++ ++ ++ ++ ++ + - visco ++ ++ ++ ++ ++ + - B7 ' reduction ++ ++ ++ ++ + + - pH ++ ++ ++ ++ + + - visco ++ ++ ++ + + - - B8 ' reduction ++ + + + - - - pH ++ ++ + + - - - visco ++ + + + + - - Table 2C '[(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m C1 ' reduction ++ ++ ++ + + + + pH ++ ++ + + + + - visco ++ + + + + + - C2 ' reduction ++ ++ + + + - - pH ++ ++ ++ + + + - visco ++ ++ + + + - - Table 2D '[(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m D1 ' reduction ++ + + + + - - pH ++ + + + + + - visco ++ + + + + + - D2 ' reduction ++ + + + + + - pH ++ + + + + - - visco ++ + + + - - - Table 2E '[(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m E1 ' reduction + + + - - - - pH + + + + - - - visco + + + - - - - E2 ' reduction ++ ++ + + + - - pH ++ ++ + + + + - visco ++ ++ ++ + + + - E3 ' reduction ++ ++ + + + - - pH ++ ++ ++ + + + + visco ++ ++ + + + - - E4 ' reduction ++ + + - - - - pH ++ + + + + - - visco ++ + + + - - - E5 ' reduction ++ ++ + + + - - pH ++ ++ ++ + + + - visco ++ ++ + + + + - Table 2F '[(40 ± 2) ° C and (75 ± 5)% rH]: 3 m 6 m 12 m 18 m 24 m 36 m 39 m F1 ' reduction + + - - - - - pH + + - - - - - visco + + + - - - - F2 ' reduction + + + - - - - pH ++ + + + - - - visco ++ + + + - - - F3 ' reduction + - - - - - - pH + + - - - - - visco + + - - - - - F4 ' reduction ++ + + - - - - pH ++ + + - - - - visco ++ + + - - - -

A characteristic measure of the stability of a composition is, on the one hand, the constancy of the pH or the viscosity and the constancy of the content of active ingredients (that is, component (a) and component (b)). Furthermore, the content of decomposition products in the composition can be determined to evaluate the stability of the composition.

Against this background, the stability studies carried out show that both the amount of the active ingredient components in the composition and their specific molecular weight and, moreover, the pH and also the buffer system used have a significant influence on the stability, in particular storage stability, of the underlying compositions , wherein the composition A1 or A1 'with the special vote of the components has the best properties in this regard.

In addition, the investigations using different buffer systems show that, in particular with the phosphate buffer system preferably used according to the invention, a further improved long-term stability can be achieved. For, as the applicant's stability studies show in a surprising manner, in particular such a phosphate buffer system brings about the desired and reliable long-term stabilization of the composition according to the invention even over long periods of time. Without wishing to be limited or limited to a specific theory, this effect of the phosphate buffer system preferably used in accordance with the invention may also be based on secondary effects, for example with regard to further stabilization of the matrix or hydrogel based on components (a) or (b) in the composition.

As evidenced by Applicants' Stability Studies above, finding a stable composition for the treatment of inflammatory diseases of the genitourinary tract, particularly inflammatory diseases of the urinary bladder, preferably of cystitis, in the nature of the present invention required extensive research by the Applicant.

Not least in their entirety, the results prove the excellent long-term stability of the composition according to the invention.

Application observations and efficacy studies

• a) Im Rahmen des ersten Untersuchungskomplexes geben die Probanden ihr subjektives Empfinden anhand einer Schulnotenskala von 1 bis 6 (1 = sehr gut bis 6 = ungenügend) an, wobei auch beliebige Zwischenwerte möglich sind. Bei dieser Untersuchung wird insbesondere auf Schmerzen im Bereich der Harnblase sowie des Beckens, übermäßigen Harndrang und auf eine kleine Harnblasenkapazität abgestellt. Es werden die jeweiligen Mittelwerte sowie die dazugehörigen Standardabweichungen ermittelt.
• b) In einer zweiten Untersuchung wird einen Monat nach der ersten Applikation der vorgenannten Zusammensetzungen bei den jeweiligen Probandengruppen eine Zystoskopie (Blasenspiegelung) durchgeführt, wobei mittels Endoskop eine visuelle Begutachtung des Blasenurothels erfolgt.
• c) Darüber hinaus werden zum Versuchsbeginn sowie nach einem Monat Urinproben genommen und der Gehalt an Glykosaminoglykan im Urin in Anlehnung an das Verfahren nach Whitley et al. (vgl. C. B., Ridnour, M. D., Draper, K. A., Dutton, C. M. and Negila, J. P.: Diagnostic test for mucoplysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin. Chem., 35: 374, 1989) ermittelt, wobei die im Urin vorhandenen Glykosaminoglykane mittels Dimethylmethylenblau angefärbt und deren Konzentrationen anschließend spektroskopisch bestimmt werden. In diesem Zusammenhang ist bekannt, dass bei Patienten mit diagnostizierter interstitieller Cystitis eine von der Konzentration bei gesunden Patienten, d. h. bei Patienten ohne Befund einer interstitiellen Cystitis, abweichende Konzentration an im Urin vorhandenem Glykosaminoglykan vorliegt. Diesbezüglich ist auch bekannt, dass bei Patienten mit einer weit fortgeschrittenen bzw. chronischen interstitiellen Cystitis der Gehalt an Glykosaminoglykan im Urin im Vergleich zu einer Kontrollgruppe ohne Befund verringert ist, während der Gehalt an Glykosaminoglykan im Urin bei Probanden mit interstitieller Cystitis im Anfangsstadium bzw. im nicht weit fortgeschrittenen Stadium erhöht ist.

Respective groups of subjects with diagnosed interstitial (ie non-bacterial) cystitis will have over a period of two months the above mentioned compositions A1 and B1, B4 (amount of chondroitin sulfate sodium); B5, B8 (amount of sodium hyaluronate); C1, C2 (molecular weight chondroitin sulfate sodium); D1, D2 (molar mass of sodium hyaluronate) and E1 and E5 (pH). Administration is by instillation into the urinary bladder. Administration is repeated weekly for a period of two months each. The volume of the instilled composition is 50 ml in each case. Per subject or composition, 10 subjects are examined. The examination intervals are 1 week, 2 weeks, 1 month and finally 2 months, each referring to the day of the first instillation. The following examination complexes are carried out:

• a) Within the framework of the first investigation complex, the subjects state their subjective feeling on the basis of a school scale from 1 to 6 (1 = very good to 6 = insufficient), although any intermediate values are possible. This study focuses on bladder and pelvic pain, excessive urinary urgency and small urinary bladder capacity. The respective averages and the associated standard deviations are determined.
• b) In a second examination, one month after the first application of the abovementioned compositions, a cystoscopy (bladder mirroring) is carried out on the respective subject groups, a visual examination of the bladder urothelium being carried out by means of an endoscope.
• c) In addition, at the beginning of the test and after one month, urine samples are taken and the content of glycosaminoglycan in the urine is modeled on the method Whitley et al. (CB, Ridnour, MD, Draper, KA, Dutton, CM and Negila, JP: Diagnostic test for mucoplysaccharidosis, I. Direct method for quantitative excretion of urinary glycosaminoglycan excretion, Clin. Chem., 35: 374, 1989). determined, wherein the present in the urine glycosaminoglycans stained by means of dimethylmethylene blue and their concentrations are then determined spectroscopically. In this context, it is known that in patients with diagnosed interstitial cystitis, there is a concentration of urinary glycosaminoglycan deviating from the concentration in healthy patients, that is, in patients without evidence of interstitial cystitis. In this regard, it is also known that in patients with advanced or chronic interstitial cystitis the content of glycosaminoglycan in the urine is reduced as compared to a control group without findings, while the content of glycosaminoglycan in the urine in subjects with interstitial cystitis in the initial stage or in the not advanced stage is increased.

The studies and efficacy studies indicate that Composition A1 has the best efficacy in treating the underlying disease in the form of interstitial cystitis as compared to the other compositions, as noted above. In particular, a significant improvement in the well-being of the health can be observed, and in addition, in the subjects of the group treated with the A1 composition there is a virtually intact bladder mucus and, in addition, no lesions and no bleeding in the urothelium. In particular, a significant decrease in the pain symptoms can be observed. There is also a significant improvement in the glycosaminoglycan content. Overall, the investigations thus also show the outstanding therapeutic effectiveness of the concept according to the invention.

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited patent literature

• WO 2004/073584 A2 [0039]
• US 6083933A [0040]

Cited non-patent literature

• 10th Edition, Volume 1, 1996, Georg Thieme Verlag Stuttgart / New York, page 736, keyword: "chondroitin sulfates" [0103]
• 10th Edition, Volume 3, 1997, Georg Thieme Verlag Stuttgart / New York, page 1820, keyword: "hyaluronic acid" [0125]
• 10th edition, Georg-Thieme-Verlag, Stuttgart / New York, Volume 4, 1998, pages 3230 to 3232, keyword: "pH" [0157]
• ASTM F 1980 [0177]
• Whitley et al. (CB, Ridnour, MD, Draper, KA, Dutton, CM and Negila, JP: Diagnostic test for mucoply saccharidosis, I. Direct method for quantifying excessive urinary glycosaminoglycan excretion, Clin. Chem., 35: 374, 1989) [0297 ]

Claims (64)

Composition, in particular pharmaceutical composition, preferably for the prophylactic and / or therapeutic treatment of preferably inflammatory diseases of the urogenital tract, in particular of inflammatory diseases of the urinary bladder, preferably of cystitis, wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts (a) chondroitin sulfate and / or a physiologically acceptable chondroitin sulfate salt (component (a)); (b) hyaluronic acid and / or a physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)); and (c) at least one local anesthetic (component (c)); contains. Composition after Claim 1 wherein the composition further comprises (d) a buffer system, in particular selected from the group of dihydrogen phosphate / monohydrogen phosphate buffer system, citric acid / citrate buffer system, carbonic acid / bicarbonate buffer system, carbonic acid / silicate buffer system and acetic acid / acetate buffer system, preferably selected from the group of dihydrogen phosphate / monohydrogen phosphate buffer system and citric acid / citrate buffer system, preferably dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)); and / or wherein the composition also contains (d) a buffer system, preferably dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)). Composition after Claim 1 or 2 wherein the composition further comprises (e) at least one physiologically acceptable electrolyte (component (e)). Composition, in particular pharmaceutical composition, preferably for the prophylactic and / or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, in particular inflammatory diseases of the urinary bladder, preferably of cystitis, preferably composition according to one of the preceding claims, wherein the composition is used in combination and in each case in effective, especially pharmaceutically effective amounts (a) chondroitin sulfate and / or a physiologically acceptable chondroitin sulfate salt (component (a)); (b) hyaluronic acid and / or a physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)); (c) at least one local anesthetic (component (c)); (d) a buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)); (e) at least one physiologically acceptable electrolyte (component (e)); contains, wherein the composition has a pH in a range of 5.5 to 8.0 and / or wherein the composition is adjusted to a pH in a range of 5.5 to 8.0. A composition according to any one of the preceding claims wherein the composition comprises the chondroitin sulfate and / or the physiologically acceptable chondroin sulfate salt (component (a)) at a concentration in a range of (2 ± 0.5) mg / ml to (25 ± 2) in particular in the range of (3 ± 0.5) mg / ml to (22 ± 2) mg / ml, preferably in the range of (4 ± 0.5) mg / ml to (20 ± 2) mg / ml. Composition according to one of the preceding Claims 1 to 5 wherein the composition comprises the chondroitin sulfate and / or the physiologically acceptable chondroin sulfate salt (component (a)) in a concentration of (20 ± 1.5) mg / ml, in particular in a concentration of (20 ± 1) mg / ml, preferably in a concentration of (20 ± 0.5) mg / ml, more preferably in a concentration of about 20 mg / ml. Composition according to one of the preceding Claims 1 to 5 in which the composition comprises the chondroitin sulfate and / or the physiologically acceptable chondroin sulfate salt (component (a)) in a concentration of (4.5 ± 0.4) mg / ml, in particular in a concentration of (4.5 ± 0, 3) mg / ml, preferably at a concentration of (4.5 ± 0.15) mg / ml, more preferably at a concentration of about 4.5 mg / ml. Composition according to one of the preceding claims, wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) has a number average molecular weight M _n in the range of 2 kDa to 200 kDa, in particular in the range of 5 kDa to 150 kDa, preferably in the range of 10 kDa up to 100 kDa, preferably in the range of 12 kDa to 75 kDa; and / or wherein the chondroitin sulfate and / or the physiologically tolerable chondroitin sulfate salt (component (a)) has a weight average molecular weight (M _w) in the range of 10 kDa to 200 kDa, in particular in the range of 15 kDa to 175 kDa, preferably in Range from 20 kDa to 150 kDa, preferably in the range of 30 kDa to 120 kDa; and / or wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) a centrifuge average molecular weight (molar mass) M _z in the range from 30 kDa to 1,000 kDa, particularly in the range of 40 kDa to 800 kDa, preferably in the Range from 50 kDa to 600 kDa, preferably in the range of 100 kDa to 450 kDa; and / or wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , of at least 1, in particular at least 1.2 , preferably at least 1.5, preferably at least 2; and / or wherein the chondroitin sulfate and / or the physiologically tolerable chondroitin sulfate salt (component (a)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , of at most 30, in particular not more than 20, preferably at most 10, preferably at most 8; and / or wherein the chondroitin sulfate and / or the physiologically tolerable chondroitin sulfate salt (component (a)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , in the range from 1 to 30, in particular Range of 1.2 to 20, preferably in the range of 1.5 to 10, preferably in the range of 2 to 8, having. Composition after Claim 8 wherein the number average molecular weight M _n and / or the weight average molecular weight M _w and / or the centrifuge average molecular weight M _z and / or the polydispersity index (PDI) of the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) by gel permeation chromatography (GPC) and / or according to DIN 55672-3: 2016-03; and / or wherein the number average molecular weight M _n and / or the weight average molecular weight M _w and / or the centrifuge average molecular weight M _z and / or the polydispersity index (PDI) of the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) by gel permeation chromatography (GPC), in particular at a temperature in the range from 20 ° C to 40 ° C and / or with 0.1 mol / l NaCl solution in deionized water as eluant and / or on a solution of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt at a concentration of 3 g / l and / or using a dextran / pullulan standard as a calibration reagent and / or according to DIN 55672-3: 2016-03. Composition according to one of the preceding claims, wherein the chondroitin sulfate and / or the physiologically tolerable chondroitin sulfate salt (component (a)) is of marine origin, in particular wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) are obtained from cartilaginous fish, in particular sharks, preferably shark cartilage, won; and or wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) is in the form of an alkali salt, preferably in the form of a sodium salt; and or wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) is in the form of chondroitin sulfate sodium (sodium chondroitin sulfate); and or wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) is selected from the group consisting of chondroitin 4-sulfate, chondroitin 6-sulfate, chondroitin 2,6-sulfate, chondroitin 4,6- sulphate and their combinations or mixtures, preferably chondroitin-2,6-sulphate (chondroitin sulphate D). A composition according to any one of the preceding claims, wherein the composition comprises the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) in a concentration ranging from (1 ± 0.5) mg / ml to (20 ± 2) in particular in a range of (2 ± 0.5) mg / ml to (18 ± 2) mg / ml, preferably in a range of (3 ± 0.5) mg / ml to (16 ± 2) mg / ml. A composition according to any one of the preceding claims wherein the composition comprises the hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (component (b)) at a concentration of (16 ± 1.2) mg / ml, especially at a concentration of (16 ± 0.8) mg / ml, preferably at a concentration of (16 ± 0.4) mg / ml, more preferably at a concentration of about 16 mg / ml. Composition according to one of the preceding claims, wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) has a number average molecular weight (molar mass) M _n in the range of 10 kDa to 300 kDa, in particular in the range of 20 kDa to 275 kDa, preferably in the range of 30 kDa to 260 kDa, preferably in the range of 50 kDa to 250 kDa, particularly preferably in the range of 50 kDa to 200 kDa; and / or wherein the hyaluronic acid and / or the physiologically tolerable hyaluronic acid salt (component (b)) has a weight average molecular weight (M _w) in the range from 10 kDa to 500 kDa, in particular in the range from 20 kDa to 450 kDa, preferably in Range from 50 kDa to 425 kDa, preferably in the range of 100 kDa to 400 kDa, more preferably in the range of 150 kDa to 395 kDa; and / or wherein the hyaluronic acid and / or the physiologically tolerable hyaluronic acid salt (component (b)) have a centrifuge-average molecular weight M _z in the range from 80 kDa to 1,500 kDa, in particular in the range from 100 kDa to 1,250 kDa, preferably in Range from 200 kDa to 1,000 kDa, preferably in the range of 300 kDa to 750 kDa; and / or wherein the hyaluronic acid and / or the physiologically tolerable hyaluronic acid salt (component (b)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , of at least 1, in particular at least 1.1 , preferably at least 1.2, preferably at least 1.3, more preferably at least 1.4; and / or wherein the hyaluronic acid and / or the physiologically tolerable hyaluronic acid salt (component (b)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , of at most 50, in particular not more than 25, preferably at most 10, preferably at most 5, more preferably at most 3; and / or wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) has a polydispersity index (PDI), calculated as the quotient of weight-average molecular weight M _w and number-average molecular weight M _n , in the range from 1 to 50, in particular Range of 1.1 to 25, preferably in the range of 1.2 to 10, preferably in the range of 1.3 to 5, particularly preferably in the range of 1.4 to 3, having. Composition after Claim 13 wherein the number average molecular weight M _n and / or the weight average molecular weight M _w and / or the centrifuge average molecular weight M _z and / or the polydispersity index (PDI) of the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) by gel permeation chromatography (GPC) and / or according to DIN 55672-3: 2016-03; and / or wherein the number average molecular weight M _n and / or the weight average molecular weight M _w and / or the centrifuge average molecular weight M _z and / or the polydispersity index (PDI) of the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) by gel permeation chromatography (GPC), in particular at a temperature in the range of 20 ° C to 40 ° C and / or with 0.1 mol / l NaCl solution in deionized water as eluant and / or on a solution of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt at a concentration of 3 g / l and / or using a dextran / pullulan standard as the calibration reagent and / or according to DIN 55672-3: 2016-03. Composition according to one of the preceding claims, wherein the ratio of the respective molecular weight M _n , M _w or M _z of chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) to the corresponding molecular weight M _n , M _w or M _z the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) in a range from 1: 3 to 1: 4, in particular 1: 1 to 1: 100, preferably 1: 1.5 to 1: 50, preferably 1: 2 to 1: 25, more preferably 1: 3 to 1:10. A composition according to any one of the preceding claims, wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) is of animal origin; and / or wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) is of bacterial and / or fermentative origin; in particular wherein the hyaluronic acid and / or the physiologically tolerable hyaluronic acid salt (component (b)) is preferably obtained by fermentation of bacteria of the genus Streptococcus, in particular Streptococcus lancefields, preferably Streptococcus lancefields strain A; and / or wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) is in the form of an alkali metal salt, preferably in the form of a sodium salt, and / or in the form of an alkali metal hyaluronate; and / or wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) is in the form of sodium hyaluronate. Composition according to one of the preceding claims, wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) on the one hand and the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) on the other hand in the composition in a Weight ratio (concentration ratio) of component (a) on the one hand to component (b) on the other hand, [(a): (b)] in a range of 2: 1 to 1: 5, especially 1.6: 1 to 1: 4, preferably 1 , 2: 1 to 1: 3.8. Composition according to one of Claims 1 to 17 wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) on the one hand and the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) on the other hand in the composition in a weight ratio (concentration ratio) of component (a) on the one hand to component (b) on the other hand, [(a): (b)] in a range of 1: 1 to 1.6: 1, in particular 1.1: 1 to 1.5: 1, preferably 1.2 : 1 to 1.4: 1, more preferably about 1.25: 1. Composition according to one of Claims 1 to 17 wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) on the one hand and the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) on the other hand in the composition in a weight ratio (concentration ratio) of component (a) on the one hand to component (b) on the other hand, [(a): (b)] in a range from 1: 3 to 1: 4, in particular 1: 3.2 to 1: 3.8, preferably 1: 3.4 to 1: 3.6, more preferably about 1: 3.55. Composition according to one of the preceding claims, wherein the composition comprises the local anesthetic (component (c)) at a concentration in a range of (0.0001 ± 0.00005) mg / ml to (100 ± 20) mg / ml, especially in a range of (0.01 ± 0.005) mg / ml to (80 ± 15) mg / ml, preferably in a range of (0.1 ± 0.05) mg / ml to (75 ± 10) mg / ml, preferably in a range of (0, 5 ± 0.1) mg / ml to (70 ± 5) mg / ml, preferably in a range of (1 ± 0.2) mg / ml to (65 ± 2) mg / ml, more preferably in a range of (5 ± 0.5) mg / ml to (60 ± 1.5) mg / ml, most preferably in a range of (10 ± 1) mg / ml to (50 ± 5) mg / ml, preferably about 20 mg / ml; and or wherein the composition comprises the local anesthetic (component (c)) in a concentration of (20 ± 19) mg / ml, in particular in a concentration of (20 ± 15) mg / ml, preferably in a concentration of (20 ± 10) mg / ml, preferably in a concentration of (20 ± 5) mg / ml, particularly preferably in a concentration of about 20 mg / ml. Composition according to one of the preceding claims, wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) and the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) on the one hand and the local anesthetic (component ( c)) on the other hand in the composition in a weight ratio (concentration ratio) of component (a) and component (b) on the one hand to component (c) on the other hand [((a) + (b)): (c)] in a range of 1 : 5 to 100: 1, in particular 1: 2 to 50: 1, preferably 1: 1 to 10: 1, preferably 1.2: 1 to 5: 1, are present. A composition according to any one of the preceding claims, wherein the local anesthetic (component (c)) is selected from the group of ester-type local anesthetics and amide-type local anesthetics, in particular from the group of benzocaine, procaine, tetracaine, lidocaine, etidocaine, prilocaine, mepivacaine, bupivacaine and S-ropivacaine or salts thereof and combinations or mixtures thereof, preferably lidocaine and / or its salts. Composition according to one of the preceding claims, the composition containing as local anesthetic (component (c)) lidocaine and / or its salts, in particular Lidocainhydrochlorid; and or wherein the local anesthetic (component (c)) is lidocaine and / or its salts, in particular lidocaine hydrochloride. A composition according to any one of the preceding claims, wherein the composition comprises the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) in a total concentration of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) within a range of (0.1 ± 0.05) mg / ml to (10 ± 1) mg / ml, especially in a range of (0.5 ± 0.05) mg / ml to (8 ± 1) mg / ml, preferably in the range of (0.75 ± 0.05) mg / ml to (5 ± 1) mg / ml, preferably in the range of (1 ± 0.05) mg / ml to (2 ± 1) mg / ml , having; and or the composition comprising the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)) in a weight ratio (concentration ratio) of dihydrogenphosphate to monohydrogenphosphate [dihydrogenphosphate: monohydrogenposphate], in particular based on the initial weight when preparing and / or providing the composition, in the range of 10: 1 to 1: 100, in particular in the range from 5: 1 to 1:75, preferably in the range from 2: 1 to 1:50, preferably in the range from 1: 1 to 1:40, particularly preferably in the range from 1: 2 to 1:30, most preferably in the range of 1: 5 to 1:25. Composition according to one of Claims 1 to 24 in which the composition comprises the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total concentration of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of (1.75 ± 1.65) mg / ml, in particular in a total concentration of (1.75 ± 1.5) mg / ml, preferably in a total concentration of (1.75 ± 1.25) mg / ml, preferably in a total concentration of (1.75 ± 1) mg / ml, more preferably in a total concentration of (1.75 ± 0.9) mg / ml, most preferably in a total concentration of (1.75 ± 0.8) mg / ml, even more preferably in one Total concentration of about 1.75 mg / ml; and / or wherein the composition comprises the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total amount of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of (87.5 ± 85) mg, in particular in a total amount of (87.5 ± 75) mg, preferably in a total amount of (87.5 ± 62.5) mg, preferably in a total amount of (87.5 ± 50) mg, more preferably in one Total amount of (87.5 ± 45) mg, most preferably in a total amount of (87.5 ± 40) mg, even more preferably in a total amount of about 87.5 mg; and / or wherein the composition comprises the dihydrogenphosphate of the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)), in particular based on the initial weight during production and / or provision of the composition, in a concentration of (0.2 ± 0.19) mg / ml, in particular in a concentration of (0.2 ± 0.15) mg / ml, preferably in a concentration of (0.2 ± 0.125) mg / ml, preferably in a concentration of (0.2 ± 0.1) mg / ml, more preferably at a concentration of about 0.2 mg / ml; and / or wherein the composition comprises the monohydrogenphosphate of the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)), in particular based on the initial weight when preparing and / or providing the composition, in a concentration of (1.5 ± 1.4) mg / ml, in particular in a concentration of (1.5 ± 1.25) mg / ml, preferably in a concentration of (1.5 ± 1.1) mg / ml, preferably in a concentration of (1.5 ± 1) mg / ml, more preferably at a concentration of (1.5 ± 0.75) mg / ml, most preferably at a concentration of about 1.5 mg / ml. Composition according to one of Claims 1 to 24 in which the composition comprises the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total concentration of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of (1 ± 0.95) mg / ml, in particular in a total concentration of (1 ± 0.9) mg / ml, preferably in a total concentration of (1 ± 0.8) mg / ml, preferably in one Total concentration of (1 ± 0.6) mg / ml, more preferably in a total concentration of (1 ± 0.4) mg / ml, most preferably in a total concentration of (1 ± 0.2) mg / ml, still further preferably in a total concentration of about 1 mg / ml; and / or wherein the composition comprises the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total amount of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of (52.5 ± 50) mg, in particular in a total amount of (52.5 ± 45) mg, preferably in a total amount of (52.5 ± 40) mg, preferably in a total amount of (52.5 ± 35) mg, more preferably in a total amount of (52.5 ± 30) mg, most preferably in a total amount of (52.5 ± 25) mg, even more preferably in a total amount of about 52.5 mg; and / or wherein the composition comprises the dihydrogenphosphate of the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)), in particular based on the initial weight when preparing and / or providing the composition, in a concentration of (0.15 ± 0.14) mg / ml, in particular in a concentration of (0.15 ± 0.12) mg / ml, preferably in a concentration of (0.15 ± 0.1) mg / ml, preferably in a concentration of (0.15 ± 0, 05) mg / ml, more preferably at a concentration of about 0.15 mg / ml; and / or wherein the composition is the monohydrogenphosphate of the dihydrogenphosphate / monohydrogenphosphate buffer system (component (d)), in particular based on the initial weight when preparing and / or providing the composition, in a concentration of (1 ± 0.9) mg / ml, in particular in a concentration of (1 ± 0.8) mg / ml, preferably in a concentration of (1 ± 0.7) mg / ml, preferably in a concentration of (1 ± 0.6) mg / ml, more preferably at a concentration of (1 ± 0.5) mg / ml, most preferably at a concentration of about 1 mg / ml. A composition according to any one of the preceding claims wherein the dihydrogen phosphate / monohydrogen phosphate buffering system (component (d)) is and / or is in the form of an alkali metal hydrogen phosphate / alkali monohydrogen phosphate buffer system; in particular wherein the alkali metal is selected from sodium and / or potassium, in particular sodium; and / or wherein the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) is present and / or formed as sodium dihydrogen phosphate / sodium monohydrogen phosphate buffer system and / or wherein the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) is NaH ₂ ( PO ₄₎ / Na ₂ H (PO ₄₎ buffer system, in particular as NaH ₂ (PO ₄₎ · 2 H ₂ O / Na ₂ H (PO ₄₎ · 2 H ₂ O-buffer system that is present and / or is formed; and / or wherein the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) serves to adjust and / or maintain the pH of the composition and / or is used. Composition according to one of the preceding claims, wherein the composition is present in the electrolyte (component (e)) in a concentration of (8 ± 6) mg / ml, in particular in a concentration of (8 ± 4) mg / ml, preferably in a concentration of (8 ± 2) mg / ml, preferably at a concentration of (8 ± 1) mg / ml, more preferably at a concentration of about 8 mg / ml; and or wherein the electrolyte (component (e)) is in the form of an alkali metal salt, in particular in the form of an alkali metal chloride, preferably in the form of sodium chloride, and / or wherein the electrolyte (component (e)) is sodium chloride. Composition according to one of the preceding claims, wherein the composition has a pH in a range of 5.5 to 8.0, in particular in a range of 5.6 to 7.8, preferably in a range of 5.7 to 7.5, preferably in a range of 5.8 to 7.2, more preferably in a range of 6.0 to 7.15; and or wherein the pH of the composition is in a range of 5.5 to 8.0, more preferably in a range of 5.6 to 7.8, preferably in a range of 5.7 to 7.5, preferably in a range of 5.8 to 7.2, more preferably in a range of 6.0 to 7.15, is kept constant and / or adjusted; and or wherein the pH is adjusted by means of the buffer system, in particular the Alkalidihydrogenphosphat / Alkalimonohydrogenposphat buffer system, (component (d)) and / or predetermined. Composition according to one of the preceding claims, wherein the composition at a temperature of 20 ° C has a dynamic viscosity of at least 2,000 mPas, in particular at least 4,000 mPas, preferably at least 5,000 mPas, preferably at least 5,250 mPas; and / or wherein the composition at a temperature of 20 ° C has a dynamic viscosity of at most 7,900 mPas, in particular at most 6,900 mPas, preferably at most 6,000 mPas, preferably at most 5,750 mPas; and / or wherein the composition at a temperature of 20 ° C has a dynamic viscosity in the range of 2,000 mPas to 7,900 mPas, in particular in the range of 4,000 mPas to 6,900 mPas, preferably in the range of 5,000 mPas to 6,000 mPas, preferably in the range of 5,250 mPas up to 5,750 mPas; Specifically determined according to the method of Ph. Eur. [Pharmacopoea Europaea], 9 ^th Edition (9.0), 2017, 9th Edition English, Section 2.2.8. "Viscosity" and Section 2.2.9. "Capillary viscometer method". A composition according to any one of the preceding claims, wherein the composition has an osmolality in the range of 150 mosmol / kg to 600 mosmol / kg, in particular in the range of 200 mosmol / kg to 550 mosmol / kg, preferably in the range of 250 mosmol / kg to 500 mosmol / kg, preferably in the range from 275 mosmol / kg to 450 mosmol / kg, more preferably in the range from 300 mosmol / kg to 400 mosmol / kg; Specifically determined according to the method of Ph. Eur. [Pharmacopoea Europaea], 9 ^th Edition (9.0), 2017, 9th Edition English, Section 2.2.5. Relative density. A composition according to any one of the preceding claims, wherein the composition at a temperature of 20 ° C and at a pressure of 1013.25 mbar (atmospheric pressure) has a density in the range 1.001 g / cm ³ to 1.5 g / cm ³ , in particular Range of 1.005 g / cm ³ to 1.25 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.1 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.075 g / cm ³ , especially preferably in the range of 1.0075 g / cm ³ to 1.05 g / cm ³ ; and / or wherein the composition at a temperature of 20 ° C and at a pressure of 1013.25 mbar (atmospheric pressure), a relative density, based on pure water, in the range of 1.001 to 1.5, in particular in the range of 1.005 to 1 , 25, preferably in the range of 1.0075 to 1.1, preferably in the range of 1.0075 to 1.075, more preferably in the range of 1.0075 to 1.05; Specifically determined according to the method of Ph. Eur. [Pharmacopoea Europaea], 9 ^th Edition (9.0), 2017, 9th Edition English, Section 2.2.35. "Osmolality". Composition according to one of the preceding claims, wherein the composition is present as an aqueous composition and / or wherein the composition is aqueous based and / or aqueous formulated, in particular in the form of an aqueous solution and / or aqueous suspension, preferably in the form of an aqueous solution; and or wherein the composition contains water, especially purified water, and / or wherein the composition contains water as a pharmaceutically acceptable carrier (excipient) and / or wherein the composition is aqueous based; and / or wherein the composition has a water content of at least 50% by weight, in particular at least 75% by weight, preferably at least 80% by weight, preferably at least 90% by weight, particularly preferably at least 95% by weight , based on the composition. Composition according to one of the preceding claims, wherein the composition of the aforementioned components (a), (b), (c), optionally (d), optionally (e) and optionally water, in particular purified water, in particular from the aforementioned components (a), (b), ( c), (d), optionally (e) and optionally water; and or wherein the composition is at least substantially free of organic solvents and / or organic dispersants, in particular alcohol-based solvents and / or alcohol-based dispersants, and / or wherein the composition is at least substantially free of alcohols; and or wherein the composition is at least substantially free of preservatives and / or at least substantially free of disinfectants. Composition according to one of the preceding claims, wherein the composition at temperatures in the range of 20 ° C to 45 ° C, at a pressure of 1013.25 mbar (atmospheric pressure) and at a relative humidity in the range of 50% to 90% at least 6 months, especially at least 12 months, preferably at least 24 months, preferably at least 36 months, stable, in particular storage stable, is; in particular wherein the composition at the respective storage time point a total content of degradation products of components (a) and (b) of at most 5%, in particular at most 4%, preferably at most 3%, preferably at most 2%, particularly preferably at most 1%, based on the total concentration the components (a) and (b); and or the composition having a stability, in particular storage stability, under accelerated aging conditions according to ASTM F 1980 at an aging temperature of 55 ° C of at least 6 months, in particular at least 12 months, preferably at least 24 months, preferably at least 36 months; in particular wherein the composition at the respective storage time point a total content of degradation products of components (a) and (b) of at most 5%, in particular at most 4%, preferably at most 3%, preferably at most 2%, particularly preferably at most 1%, based on the total concentration of components (a) and (b). Composition according to one of the preceding claims, wherein the composition is an alkaline earth salt concentration, in particular calcium salt concentration and / or magnesium salt concentration, of at most 1 mg / ml, in particular at most 0.5 mg / ml, preferably at most 0.1 mg / ml , preferably at most 0.05 mg / ml, more preferably at most 0.01 mg / ml; and / or wherein the composition is at least substantially free of alkaline earth salts, in particular at least substantially free of calcium salts and / or magnesium salts; and / or wherein the composition has an alkaline earth metal concentration, in particular calcium concentration and / or magnesium concentration, of at most 1 mg / ml, in particular at most 0.5 mg / ml, preferably at most 0.1 mg / ml, preferably at most 0 0.05 mg / ml, more preferably at most 0.01 mg / ml; and / or wherein the composition is at least substantially free of alkaline earth metals, in particular at least substantially free of calcium and / or magnesium salts; and or wherein the composition has a concentration of bivalent ions, in particular bivalent cations, preferably alkaline earth ions, preferably calcium ions and / or magnesium ions, of at most 1 mg / ml, in particular at most 0.5 mg / ml, preferably at most 0.1 mg / ml, preferably at most 0.05 mg / ml, more preferably at most 0.01 mg / ml; and / or wherein the composition is at least substantially free of bivalent ions, in particular bivalent cations, preferably alkaline earth metal ions, preferably calcium ions and / or magnesium ions. Composition according to one of the preceding claims, wherein the composition, in particular application, dosing and / or ready for application, with a volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferred (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml; and / or wherein the composition, in particular application, dosing and / or ready for administration, for administration, in particular instillation into the bladder, a volume of the composition of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, is present and / or prepared or wherein the composition, in particular application, dosing and / or ready for application, in particular by means of instillation into the urinary bladder, with a volume of the composition of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, particularly preferred (50 ± 0.5) ml, most preferably about 50 ml; and / or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in one Range from (100 ± 25) mg to (1250 ± 100) mg, especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) mg to ( 1,250 ± 100) mg, especially in the range of (150 ± 10) mg to (1100 ± 100) mg, preferably in the range of (200 ± 10) mg to (1000 ± 100) mg, and / or prepared or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) mg to (1250 ± 100) mg, especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (1,000 ± 100) mg, in particular (1,000 ± 75 ) mg, preferably (1,000 ± 50) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient of chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (1,000 ± 100) mg, in particular (1,000 ± 75) mg, preferably (1000 ± 50) mg, is present and / or prepared or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (1,000 ± 100) mg, especially (1,000 ± 75) mg, preferably (1,000 ± 50) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (225 ± 25) mg, in particular (225 ± 15 ) mg, preferably (225 ± 10) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (225 ± 25) mg, in particular (225 ± 15) mg, preferably (225 ± 10) mg, is present and / or prepared or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) of (225 ± 25) mg, especially (225 ± 15) mg, preferably (225 ± 10) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in a range of (50 ± 25) mg to (1,000 ± 100) mg, especially in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in a range of (50 ± 25) in particular in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg, and / or or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in a range of (50 ± 25 ) to (1000 ± 100) mg, especially in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg ; and / or wherein the composition, in particular application, dosing and / or ready for application, with an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) of (800 ± 80) mg, in particular ( 800 ± 60) mg, preferably (800 ± 40) mg; and / or wherein the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient of hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) of (800 ± 80) mg, in particular (800 ± 60) mg, preferably (800 ± 40) mg, is present and / or prepared or wherein the composition, in particular application, dosing and / or application ready, with an amount of active ingredient of hyaluronic acid and / or physiologically acceptable Hyaluronsäure- Salt (hyaluronate) (component (b)) of (800 ± 80) mg, especially (800 ± 60) mg, preferably (800 ± 40) mg. Composition according to one of the preceding claims, wherein the composition, in particular application, dosing and / or ready for application, with a drug amount of local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2500 ± 250) mg, in particular in one area from (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg; and or wherein the composition, in particular application, dosing and / or ready for application, for administering an amount of active ingredient to local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2500 ± 250) mg, in particular in one Range from (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg), and / or wherein the composition, in particular , Dosage and / or ready to use, with an amount of local anesthetic agent (component (c)) in a range of (1 ± 0.5) mg to (2.500 ± 250) mg, especially in a range of (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg; and or wherein the composition, in particular application, dosing and / or ready to use, with an amount of local anesthetic (component (c)) of (1,000 ± 900) mg, in particular (1,000 ± 500) mg, preferably (1,000 ± 100) mg, is present; and or wherein the composition, in particular application, dosing and / or ready for administration, for administering an amount of active ingredient to local anesthetic (component (c)) of (1,000 ± 900) mg, in particular (1,000 ± 500) mg, preferably (1,000 ± 100) mg , is present and / or prepared or wherein the composition, in particular application, dosage and / or application ready, with an amount of active local anesthetic (component (c)) of (1,000 ± 900) mg, in particular (1,000 ± 500) mg , preferably (1,000 ± 100) mg. Composition according to one of the preceding claims, wherein the composition in a storage and / or application device, in particular in a storage and / or application container, is introduced and / or present, in particular application, dosing and / or application is introduced and / or present; and or wherein the composition is present in particular application, dosing and / or ready for application in a storage and / or application device, in particular in a storage and / or application container, preferably in volume sizes of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, per container or application unit (dosing unit); in particular wherein the storage and / or application device is a preferably sterile syringe, in particular syringe, preferably disposable syringe, in particular with a receiving and / or filling volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml. Composition according to one of the preceding claims for instillation and / or preferably topical application in the urogenital area, in particular in the urinary bladder; and / or wherein the composition for administration and / or instillation and / or for preferably topical application in the urogenital tract, in particular in the urinary bladder, is prepared or wherein the Composition by instillation and / or for preferably topical application in the urogenital tract, especially in the urinary bladder, is administered. Composition according to one of the preceding claims for use in the prophylactic and / or therapeutic treatment of preferably inflammatory diseases of the genitourinary tract, in particular of inflammatory diseases of the bladder, preferably of cystitis, in particular acute or chronic cystitis, preferably interstitial cystitis, radiogenic cystitis, chronic recurrent cystitis , Chemocystitis, chronic abacterial cystitis and chronic bacterial cystitis, especially preferred interstitial cystitis. Composition according to one of the preceding claims for the prophylactic and / or therapeutic treatment of preferably inflammatory diseases of the urogenital tract, in particular of inflammatory diseases of the urinary bladder, preferably of cystitis, in particular acute or chronic cystitis, preferably interstitial cystitis, radiogenic cystitis, chronic recurrent cystitis, chemocystitis, chronic abacterial cystitis and chronic bacterial cystitis, especially preferred interstitial cystitis. Use of a composition according to one of the preceding claims for the prophylactic and / or therapeutic treatment of preferably inflammatory diseases of the urogenital tract, in particular inflammatory diseases of the urinary bladder, preferably of cystitis, in particular acute or chronic cystitis, preferably interstitial cystitis, radiogenic cystitis, chronic recurrent cystitis, Chemocystitis, chronic abacterial cystitis and chronic bacterial cystitis, especially preferred interstitial cystitis. Use of a composition according to any one of the preceding claims for the manufacture of a medicament and / or medicament for the prophylactic and / or therapeutic treatment of preferably inflammatory diseases of the urogenital tract, in particular inflammatory diseases of the urinary bladder, preferably of cystitis, in particular acute or chronic cystitis, preferably interstitial cystitis , radiogenic cystitis, chronic recurrent cystitis, chemocystitis, chronic abacterial cystitis, and chronic bacterial cystitis, most preferably interstitial cystitis. A composition according to any one of the preceding claims or use according to Claim 43 or 44 , wherein the composition having a volume of the composition of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml, and / or an amount of active ingredient in chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) mg to (1250 ± 100) mg, especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg, and / or an amount of hyaluronic acid and / or physiologically acceptable hyaluronic acid Salt (hyaluronate) (component (b)) in a range of (50 ± 25) mg to (1000 ± 100) mg, especially in a range of (100 ± 25) mg to (900 ± 100) mg, preferably in one Range of (150 ± 25) mg to (800 ± 100) mg, and / or an amount of local anesthetic agent (component (c)) in a range of (1 ± 0, 5) mg to (2,500 ± 250) mg, especially in a range of (10 ± 1) mg to (2,000 ± 200) mg, preferably in a range of (100 ± 1) mg to (1,500 ± 150) mg, especially at least once a week, preferably over a period of preferably at least one month, into the bladder and / or instilled and / or preferably applied topically and / or for at least weekly administration (at least once a week), preferably over a period of preferably at least one month, by instillation and / or topical application into the urinary bladder, or wherein the composition is administered at least once a week, preferably over a period of preferably at least one month, by instillation and / or topical application to the urinary bladder. Storage and / or application device, in particular storage and / or application container, in particular in the form of a preferably sterile syringe, in particular syringe, preferably disposable syringe, preferably for instillation and / or preferably topical application in the urogenital area, in particular in the urinary bladder, containing a composition according to any one of the preceding claims. Storage and / or application device, in particular storage and / or application container, in particular in the form of a preferably sterile syringe, in particular syringe, preferably disposable syringe, preferably for instillation and / or preferably topical application in the urogenital area, in particular in the urinary bladder, containing a composition, in particular a composition according to one of the preceding claims, wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts (a) chondroitin sulfate and / or a physiologically acceptable chondroitin sulfate salt (component (a)); (b) hyaluronic acid and / or a physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)); and (c) at least one local anesthetic (component (c)); contains. Storage and / or application device according to Claim 46 or 47 wherein the composition further comprises (d) a buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)). Storage and / or application device according to one of Claims 46 to 48 wherein the composition further comprises (e) at least one physiologically acceptable electrolyte (component (e)). Storage and / or application device according to one of Claims 46 to 49 wherein the storage and / or application device a receiving and / or filling volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, particularly preferred (50 ± 0.5) ml, most preferably about 50 ml. Storage and / or application device according to one of Claims 46 to 50 wherein the composition comprises an amount of active ingredient of (a) chondroitin sulfate and / or physiologically acceptable chondroitin sulfate salt (component (a)) in a range of (100 ± 25) mg to (1250 ± 100) mg, especially in a range of (150 ± 10) mg to (1100 ± 100) mg, preferably in a range of (200 ± 10) mg to (1000 ± 100) mg; and / or wherein the composition comprises an amount of active ingredient of (b) hyaluronic acid and / or physiologically acceptable hyaluronic acid salt (hyaluronate) (component (b)) in a range of (50 ± 25) mg to (1000 ± 100) mg, in particular a range of (100 ± 25) mg to (900 ± 100) mg, preferably in a range of (150 ± 25) mg to (800 ± 100) mg; and / or wherein the composition comprises an amount of active ingredient of (c) local anesthetic (component (c)) in a range of (1 ± 0.5) mg to (2500 ± 250) mg, especially in a range of (10 ± 1) mg to (2,000 ± 200) mg, preferably within a range of (100 ± 1) mg to (1,500 ± 150) mg. Storage and / or application device according to one of Claims 46 to 51 wherein the composition comprises the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total amount of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of (87.5 ± 85) mg , in particular in a total amount of (87.5 ± 75) mg, preferably in a total amount of (87.5 ± 62.5) mg, preferably in a total amount of (87.5 ± 50) mg, most preferably in a total amount of (87.5 ± 45) mg, most preferably in a total amount of (87.5 ± 40) mg, even more preferably in a total amount of about 87.5 mg. Storage and / or application device according to one of Claims 46 to 51 wherein the composition comprises the buffer system, in particular the dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) in a total amount of buffer system, in particular dihydrogen phosphate / monohydrogen phosphate buffer system, (component (d)) of (52.5 ± 50) mg , in particular in a total amount of (52.5 ± 45) mg, preferably in a total amount of (52.5 ± 40) mg, preferably in a total amount of (52.5 ± 30) mg, more preferably in a total amount of ( 52.5 ± 25) mg, most preferably in a total amount of (52.5 ± 20) mg, even more preferably in a total amount of about 52.5 mg. Storage and / or application device according to one of Claims 46 to 53 wherein the composition of the electrolyte (component (e)) in an amount of (400 ± 300) mg, in particular in an amount of (400 ± 200) mg, preferably in an amount of (400 ± 100) mg, preferably in a Amount of (400 ± 50) mg, more preferably in an amount of about 400 mg contains. Storage and / or application device according to one of Claims 46 to 54 . wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) is in the form of an alkali salt, preferably in the form of a sodium salt; and / or wherein the chondroitin sulfate and / or the physiologically acceptable chondroitin sulfate salt (component (a)) is in the form of chondroitin sulfate sodium (sodium chondroitin sulfate); and / or wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) is in the form of an alkali metal salt, preferably in the form of a sodium salt, and / or in the form of an alkali metal hyaluronate; and / or wherein the hyaluronic acid and / or the physiologically acceptable hyaluronic acid salt (component (b)) is in the form of sodium hyaluronate; and / or wherein the local anesthetic (component (c)) is selected from the group of ester-type local anesthetics and amide-type local anesthetics, in particular from the group of benzocaine, procaine, tetracaine, lidocaine, etidocaine, prilocaine, mepivacaine, bupivacaine and s-ropivacaine or their salts and their combinations or mixtures, preferably lidocaine and / or its salts; and / or wherein the composition contains as local anesthetic (component (c)) lidocaine and / or its salts, in particular Lidocainhydrochlorid; and / or wherein the local anesthetic (component (c)) is lidocaine and / or its salts, in particular lidocaine hydrochloride; and / or wherein the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) is present and / or formed as an alkali metal hydrogen phosphate / alkali monohydrogen phosphate buffer system; in particular wherein the alkali metal is selected from sodium and / or potassium, in particular sodium; and / or wherein the dihydrogen phosphate / monohydrogen phosphate buffer system (component (d)) is present and / or formed as a sodium dihydrogen phosphate / sodium monohydrogen phosphate backbone system; and / or wherein the electrolyte (component (e)) is in the form of an alkali metal salt, in particular in the form of an alkali chloride, preferably in the form of sodium chloride, and / or is formed and / or wherein the electrolyte (component (e)) is sodium chloride. Storage and / or application device according to one of Claims 46 to 55 wherein the composition has a pH in a range of 5.5 to 8.0, in particular in a range of 5.6 to 7.8, preferably in a range of 5.7 to 7.5, preferably in a range from 5.8 to 7.2, more preferably in a range of 6.0 to 7.15; and / or wherein the pH of the composition is in a range from 5.5 to 8.0, in particular in a range from 5.6 to 7.8, preferably in a range from 5.7 to 7.5, preferably in a range of 5.8 to 7.2, more preferably in a range of 6.0 to 7.15, kept constant and / or adjusted; and / or wherein the pH by means of the buffer system, in particular the Alkalidihydrogenphosphat / Alkalimonohydrogenposphat buffer system, (component (d)) adjusted and / or predetermined. Storage and / or application device according to one of Claims 46 to 56 wherein the composition at a temperature of 20 ° C has a dynamic viscosity of at least 2,000 mPas, in particular at least 4,000 mPas, preferably at least 5,000 mPas, preferably at least 5,250 mPas; and / or wherein the composition at a temperature of 20 ° C has a dynamic viscosity of at most 7,900 mPas, in particular at most 6,900 mPas, preferably at most 6,000 mPas, preferably at most 5,750 mPas; and / or wherein the composition at a temperature of 20 ° C has a dynamic viscosity in the range of 2,000 mPas to 7,900 mPas, in particular in the range of 4,000 mPas to 6,900 mPas, preferably in the range of 5,000 mPas to 6,000 mPas, preferably in the range of 5,250 mPas up to 5,750 mPas; and / or wherein the composition has an osmolality in the range of 150 mosmol / kg to 600 mosmol / kg, in particular in the range of 200 mosmol / kg to 550 mosmol / kg, preferably in the range of 250 mosmol / kg to 500 mosmol / kg in the range of 275 mosmol / kg to 450 mosmol / kg, more preferably in the range of 300 mosmol / kg to 400 mosmol / kg; and / or wherein the composition at a temperature of 20 ° C and at a pressure of 1013.25 mbar (atmospheric pressure), a density in the range of 1.001 g / cm ³ to 1.5 g / cm ³ , in particular in the range of 1.005 g / cm ³ to 1.25 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.1 g / cm ³ , preferably in the range of 1.0075 g / cm ³ to 1.075 g / cm ³ , more preferably in the range of 1.0075 g / cm ³ to 1.05 g / cm ³ ; and / or wherein the composition at a temperature of 20 ° C and at a pressure of 1013.25 mbar (atmospheric pressure), a relative density, based on pure water, in the range of 1.001 to 1.5, in particular in the range of 1.005 to 1 , 25, preferably in the range of 1.0075 to 1.1, preferably in the range of 1.0075 to 1.075, particularly preferably in the range of 1.0075 to 1.05. Storage and / or application device according to one of Claims 46 to 57 . wherein the storage and / or application device, the composition, in particular application, dosing and / or ready for application, with a volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferred (50 ± 1) ml, more preferably (50 ± 0.5) ml, most preferably about 50 ml; and / or wherein the composition has a volume of (50 ± 10) ml, in particular (50 ± 5) ml, preferably (50 ± 2) ml, preferably (50 ± 1) ml, particularly preferably (50 ± 0.5) ml, most preferably about 50 ml, is present. Storage and / or application device according to one of Claims 46 to 58 wherein the composition is present as an aqueous composition and / or wherein the composition is aqueous based and / or aqueous formulated, in particular in the form of an aqueous solution and / or aqueous suspension, preferably in the form of an aqueous solution; and / or wherein the composition contains water, in particular purified water, and / or wherein the composition contains water as a pharmaceutically acceptable carrier (excipient) and / or wherein the composition is formed aqueous based; and / or wherein the composition has a water content of at least 50% by weight, in particular at least 75% by weight, preferably at least 80% by weight, preferably at least 90% by weight, particularly preferably at least 95% by weight , based on the composition. Storage and / or application device according to one of Claims 46 to 59 , wherein the composition of the aforementioned components (a), (b), (c), optionally (d), optionally (e) and optionally water, in particular from the aforementioned components (a), (b), (c) and optionally (d) and optionally water. Packaging unit containing at least one storage and / or application device according to one of Claims 46 to 60 , In particular wherein the storage and / or application device is present in a protective against contamination outer packaging. Kit, in particular instillation system, comprising (i) at least one storage and / or application device according to one of Claims 46 to 60 , (ii) at least one composition according to one of the preceding claims, in particular wherein the composition is preferably present in the storage and / or application device ready for application, dosing and / or application, and (iii) at least one of the storage and / or Application device connectable instillation device, in particular in the form of an instillation tube or the like. Use according to one of Claims 43 to 45 , Storage and / or application device according to one of Claims 46 to 60 , Packaging unit after Claim 61 and / or kit Claim 62 characterized by one or more features of Claims 1 to 42 , Composition according to one of Claims 1 to 42 , Use according to one of Claims 43 to 45 , Storage and / or application device according to one of Claims 46 to 60 , Packaging unit after Claim 61 and / or kit Claim 62 , wherein the prophylactic and / or therapeutic treatment of the preferably inflammatory diseases of the genitourinary tract, in particular of the inflammatory diseases of the bladder, preferably of cystitis, particularly preferably of interstitial cystitis, comprises a symptomatic and / or topical (local) pain treatment and / or pain therapy.